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The impact of T cell senescence during ageing is well established. However, T cell 
senescence is now recognised to play a role in a variety of age-related and metabolic 
diseases, such as rheumatoid arthritis and cardiovascular disease. It is therefore 
crucial to gain a better understanding of the mechanisms that control T cell 
senescence. The loss of mitochondria has been linked to both cellular senescence 
and ageing; however, it is still unclear whether mitochondria play a causal role in T 
cell senescence. Data presented here provides evidence that the differing 
susceptibilities to senescence that exist between CD8+ and CD4+ T cells is due to the 
inherent differences in mitochondrial content and cellular metabolism. Notably CD4+ 
T cells displayed a higher mitochondrial mass, shown to be the result of a GATA3-
PGC1a complex, which is recruited as a consequence of DNA damage.  
 
Additionally, this thesis demonstrates the existence of a novel naïve-like senescent T 
cell subset, highlighting the heterogeneity of senescent T cells. This subset was found 
to arise because of inflammation; therefore, senescent T cells isolated from people 
living with type 2 diabetes (T2D) were used as a model to examine the characteristics 
of this subset further. Inflammatory-derived senescent T cells were phenotypically 
distinct to those examined from healthy age-matched control donors. With T2D 
senescent T cells expressing fewer of the traditional senescent-associated T cell 
markers and retaining more proliferative capacity, indicating they were derived from 




cells exhibited more severe mitochondrial dysfunction and dysregulated nutrient 
uptake and usage.  
 
Collectively, this thesis highlights the heterogeneity of senescent T cells and supports 
the ever-growing appreciation that cellular metabolism and senescence are 
intimately linked. Going forward, mitochondrial health and cellular metabolism 
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Chapter one: Introduction 
1.1. What is cellular senescence? 
Cellular senescence is a process in which cells enter a state of stable cell cycle arrest. 
However, despite being unable to proliferate, senescent cells remain metabolically 
active. The term cellular senescence was first introduced over five decades ago when 
Hayflick and Moorhead discovered that human fibroblasts have a finite proliferative 
capacity in culture (Hayflick and Moorhead, 1961). This phenomenon was described 
as the Hayflick limit and found to reflect a particular type of cellular senescence 
known as replicative senescence. It was later revealed that replicative senescence is 
causally linked to telomere erosion due to extensive proliferation in the absence of 
telomerase activity (Bodnar et al., 1998). In the early 1970s, Olovnikov (Olovnikov, 
1971) and Watson (Watson, 1972) independently described this as the end-
replication problem. As a result, telomeres are thought to represent a molecular 
clock that reflects the replicative age of a cell (Harley et al., 1990). Historically cellular 
senescence was viewed as an irreversible mechanism that acted to prevent cancer; 
however, recent discoveries have implicated senescence in many physiological roles 
such as embryonic development (Muñoz-Espín et al., 2013; Storer et al., 2013), tissue 
repair (Krizhanovsky et al., 2008), wound healing (Jun and Lau, 2010), organismal 
ageing (Baker et al., 2008, 2011) and paradoxically, tumorigenesis (Muñoz-Espín and 





1.1.1. The senescence phenotype 
Phenotypically senescent cells are very distinctive. Senescent fibroblasts have been 
shown to exhibit a flat, enlarged morphology and accumulate senescence associated 
β-galactosidase activity (Dimri et al., 1995). Some senescent cells can also be 
identified by the cytological markers of senescence-associated heterochromatin foci, 
which are specialised domains of heterochromatin that contribute to the silencing of 
genes that promote proliferation (Narita et al., 2003, 2006). Furthermore, senescent 
cells secrete a complex pool of senescence associated secretory phenotype (SASP) 
factors that are comprised of pro-inflammatory cytokines, chemokines, growth 
factors and proteases (Coppe et al., 2006; Kuilman and Peeper, 2009). SASP factors 
are highly pleiotropic and can impact numerous biological processes. For instance, 
the SASP is able to reinforce senescence in a cell-autonomous manner as well as 
transmit senescence to neighbouring cells in a paracrine manner (Figure 1.1). 
 
The response of neighbouring cells to SASP components depends on the cell type and 
cell context. For example, the SASP can stimulate angiogenesis (Coppe et al., 2006), 
increase proliferation of nearby cells potentially resulting in tumorigenesis (Krtolica 
et al., 2001), promote the invasion of neoplastic cells via an epithelial to 
mesenchymal transition (Bavik et al., 2006; Laberge et al., 2012), and disrupt normal 
tissue structures and function. Interestingly, one of the functions of the SASP is to 
attract immune cells such as natural killer (NK) cells, CD4+ Th1 cells, CD8+ and M1 
macrophages, which in turn orchestrate the clearance of senescent cells by 





Figure 1.1: The effect of SASP factors on tissue homeostasis 
SASP factors are highly pleiotropic and can impact many biological processes. The response 
of neighbouring cells depends on both the cell type and cell context. In addition to being able 
to transmit senescence in an autocrine and paracrine manner, it is now recognised that 
senescence can play a role in tumorigenesis as many SASP factors are able to stimulate 
angiogenesis, increase proliferation of nearby cells and promote invasion of nearby 




1.1.2. Replicative senescence 
Replicative senescence is the process of cell cycle arrest attributed to telomere 
erosion. Telomeres are stretches of repetitive DNA sequences at the terminal regions 
of chromosomes. As a cell divides it loses between 50-200 base pairs of telomeric 
DNA during each S phase (Harley et al., 1990). Telomere length can be maintained by 
the ribonucleoprotein enzyme telomerase, which contains telomerase reverse 
transcriptase (TERT), a catalytic protein component that uses an RNA template 
sequence to add TTAGGG repeats to the chromosome ends (Collins and Mitchell, 
2002). TERT is expressed in cells with high proliferation rates such as germ-line cells 
and cancer cells. However, most normal somatic cells express levels of TERT that are 
too low to prevent telomere erosion, or no TERT at all (Masutomi et al., 2003).  
 
Critically short telomeres trigger a DNA damage response (DDR), which involves 
tumour suppressor pathways governed by the transcriptional regulators p53 and 
retinoblastoma (pRB) (Figure 1.2). These establish and maintain cell cycle arrest 
through the activation of cyclin dependent kinase inhibitor (CDKI) p21, which is 
directly induced by p53 and results in the inhibition of the cyclin E and cyclin 
dependent kinase (CDK) 2 complex. The regulation of p53 and pRB is also linked to 
the INK4a/ARF locus, which encodes two important tumour suppressor genes: p14 
(Arf) and p16 (Ink4a) (Sherr, 2001). Ultimately, these pathways halt cell cycle 
progression by preventing the inactivation of pRB, therefore resulting in continued 






Figure 1.2: Molecular mechanisms of cellular senescence 
During normal cell cycle progression, CDK-cyclin complexes phosphorylate pRB. 
Phosphorylation allows pRB to disassociate from the transcription factor E2F, liberating E2F 
from the cytoplasm and allowing it to enter the nucleus where it is able to activate the 
transcription of target genes that are crucial for transition from G1 phase to S phase. 
Senescence stimuli such as DNA damage is initially detected by key DDR protein kinases 
ataxia telangiectasia mutated (ATM) and/or ataxia telangiectasia and Rad3-related (ATR), 
resulting in activation p53.  This results in the upregulation of p21, leading to the inhibition 
of cyclin E-CDK2, which in turn inhibits the repression of pRB, causing cell cycle arrest. The 
Ink4a/Arf locus is also linked to replicative senescence. p14 regulates p53 stability through 
inactivation of the p53 degrading E3 ubiquitin protein ligase MDM2. Whereas p16, halts cell 




1.1.3. Premature senescence  
Senescence can also be induced by various different stimuli in the absence of any 
detectable telomere erosion. This type of senescence is known as premature 
senescence. Prolonged cellular stresses such as non-telomeric DNA damage, hypoxia 
and increased reactive oxygen species (ROS) production have all been shown to 
induce premature senescence (Chen et al., 1995). Similar to telomere erosion these 
stresses can drive cell cycle arrest through either p53 or p16 (Lin et al., 1998; Serrano 
et al., 1997). For example, mechanistically increased intracellular levels of ROS have 
been shown to activate the p38 mitogen-activated protein kinase (MAPK), which in 
turn activates the p53 pathway (Passos et al., 2010). 
 
1.1.4. Oncogene induced senescence 
Despite the traditional view that activated oncogenes promote uncontrollable 
proliferation, oncogenes are also prominent inducers of senescence. This discovery 
came when an oncogenic form of RAS (H-ras-V12) generated fibroblasts that 
phenotypically resembled that of replicative senescent fibroblasts (Serrano et al., 
1997). The list of oncogenes that are able to induce senescence has since risen to 
above 50 and includes oncogenes such as E2F1 (Dimri et al., 2009), Raf (Zhu et al., 
1998), Mos, Cdc6 and Cyclin E (Bartkova et al., 2006). Interestingly, oncogenes are 
able to induce senescence through a variety of different mechanisms. For example, 
BRAFV600E can induce senescence through both p16 activation and through a 
metabolic effector pathway involving the upregulation of the mitochondrial enzyme 




metabolic shift from glycolysis towards oxidative phosphorylation (OXPHOS), which 
in turn results in high levels of ROS production and the induction of senescence 
(Kaplon et al., 2013). 
 
1.2. Immunosenescence and ageing 
In the context of the immune system, senescence is known as immunosenescence 
and refers to the gradual deterioration of immune function that occurs with age 
(Dorshkind et al., 2009). For the first time in history, older individuals constitute the 
fastest growing population in the world, with world health organisation projections 
indicating that between 2015 and 2050 the proportion of the world’s population over 
60 years will double from 12% to 22% (World Health Organization, 2015). 
Immunosenescence can result in reduced adaptive immunity, leaving older 
individuals unable to respond to new vaccinations. Furthermore, this deterioration 
leaves older individuals more susceptible to infectious diseases. And an imbalance in 
the innate immune system, which is also associated with immunosenescence, can 
lead to chronic inflammation and trigger autoimmune and other age-related diseases 
(Bruunsgaard, 2006; Larbi et al., 2008; Licastro et al., 2005). Consequently, a better 
understanding of the biological mechanisms responsible for immunosenescence is 






1.2.1. The immune system 
The immune system refers to a combination of specialised organs, cells and proteins 
that work together in order to protect against foreign organisms and pathogens. 
There are two arms of the immune system: innate immunity and adaptive immunity. 
The innate system is comprised of physical and chemical barriers such as epithelial 
barriers and gastric acid, which act as a first line of defence against pathogens. In 
addition to this, the innate system also comprises a second line of defence, which 
includes complement factors and many immune cells from the myeloid lineage such 
as neutrophils, macrophages, mast cells, basophils, eosinophils, NK cells and 
dendritic cells (DC). This arm of the immune system is rapid and antigen independent. 
By contrast, the adaptive system, consisting of T and B cells from the lymphocyte 
lineage, is an antigen-dependent and antigen-specific response. Consequently, the 
adaptive system requires more time to mount a biological response. Importantly, the 
adaptive immune response is able to build an immunologic memory, which enables 
the host to mount a much more rapid and efficient immune response following 
repeat exposure to an antigen. Whilst the role of each arm of the immune system is 
different, innate and adaptive immunity are not mutually exclusive. Instead, the two 
systems compliment and communicate with one another in order to orchestrate an 
effective immune response and as a result, defects in either system can result in host 





1.2.2. Innate immune cell senescence and inflammageing 
Immunosenescence in the innate immune system is considerably complex. The total 
number of myeloid progenitors does not decrease as we age. In fact some studies 
have documented that aged haematopoietic stem cells (HSCs) become biased 
towards myeloid differentiation and therefore age could result in an increase in 
myeloid cells (Beerman et al., 2010; Cho et al., 2008). Furthermore, as innate immune 
cells tend to be short lived, they are less likely to senesce. Instead 
immunosenescence in the innate immune system is thought to reflect cellular 
dysfunction (Shaw et al., 2013). This dysfunction is characterised by persistent 
systemic inflammation that occurs in the absence of any infections (sterile 
inflammation). As the levels of cytokines are far lower than the levels released in 
response to an acute inflammatory response, this age-associated dysfunction instead 
results in chronic low–grade inflammation and has consequently been termed 
inflammageing (Franceschi et al., 2000; Shaw et al., 2010).  
 
1.2.3. Adaptive immune cell senescence 
Ageing affects both the quantity and the quality of humoral and T cell immunity 
(Naylor et al., 2005; Weksler, 2000). Unlike myeloid cells, there is a gradual decrease 
in the total number of lymphoid progenitors as we age (Johnson, 2002). Due to the 
long-lived nature of memory lymphocytes, the adaptive immune system is 
particularly sensitive to senescence. The percentage of late memory B cells are 
increased in older individuals. Furthermore, these cells exhibit many hallmarks of 




expression (Frasca et al., 2017). Functionally senescent B cells have been shown to 
secrete less antibodies, which also have a decreased affinity for antigen (Frasca et al., 
2008). Similarly, the percentage of terminally differentiated T cells, which exhibit 
both phenotypic and functional senescent properties, also increases with age 
(Henson et al., 2012, 2014). Moreover, both senescent B cells and senescent T cells 
have recently been shown to secrete a SASP (Callender, Carroll, Beal, et al., 2018; 
Frasca et al., 2017), however the main SASP components are distinct from that  
secreted by senescent fibroblasts (Table 1.1).  
 
Table 1.1: Comparison of fibroblast SASP with CD8+ EMRA T cell SASP [Adapted from 
(Callender, Carroll, Bober, et al., 2018)]. 
 Fibroblast SASP  
Cytokines & 
chemokines 
Replicative OIS MiDAS 
T cell SASP 
IL-1α +++ +++ − + 
IL-1β + ++ − + 
IL-6 ++ +++ − + 
IL-8 +++ +++ − + 
IL-18 + ? − +++ 
TNFα + + + + 
IFN-γ + + − + 
CCL5 + + − + 
CCL27 − − + − 
Proteases     
MMP-1, -3, -10 + + − + 
ADAM8 + ? ? + 
ADAMTS1 + ? ? + 
ADAM28 ? ? ? +++ 
Growth factors     




1.2.4. T cell maturation 
All immune cells, including T cells, develop from HSCs in the bone marrow in a process 
called haematopoiesis. During T cell development, committed lymphoid progenitor 
cells (LPCs) migrate out of the bone marrow and into the thymus where they lose the 
potential for B cell (Pui et al., 1999; Radtke et al., 1999) and NK cell (Michie et al., 
2000) development. At this stage T cells lack a T cell receptor (TCR), as well as a CD4 
and/or CD8 receptor and are therefore termed double negative (DN) thymocytes 
(Figure 1.3). Effective T cell immunity is dependent on a diverse TCR repertoire. This 
diversity is generated through a series of recombination events in the thymus which 
allows 108 specificities to be generated from just a finite number of genes. Following 
successful gene recombination, cells become double positive (DP) CD4+CD8+ T cells, 
which interact with cortical epithelial cells and undergo stringent negative selection 
tests to remove any self-recognising or inadequate thymocytes. Positive selection 
then allows a small fraction of DP cells to mature into single positive CD4+ or CD8+ 
naïve T cells, which migrate out of the thymus and into peripheral tissue where they 
circulate through secondary lymphoid organs awaiting an encounter with an antigen  







Figure 1.3: T cell development 
T cells develop from HSCs. Committed LPCs migrate to the thymus where they begin as DN 
thymocytes. DN thymocytes can be subdivided into four stages of differentiation; DN1, DN2, 
DN3 and DN4. Through genetic recombination events, DN T cells can give rise to either αβ or 
less frequently, γδ TCR expressing cells. With regards to the αβ TCR, during DN3 to DN4 
stages, T cells express the pre-TCR, composed of a rearranged TCR β-chain and a non-




replacement of the pre TCR α-chain with a rearranged TCR α-chain, yielding a complete αβ 
TCR. At this stage T cells are termed DP as they express both CD4+ and CD8+. The fate of the 
DP thymocytes is then decided through interactions with cortical epithelial cells that express 
MHC class I and class II molecules associated with self-peptide. Too weak or too strong a 
signal results in apoptosis. The appropriate level of TCR signalling initiates positive selection, 
allowing maturation into either CD4+ or CD8+ single positive T cells that migrate out of the 
thymus and into the circulation [Adapted from (Engel and Murre, 2001; Germain, 2002)].  
 
1.2.4.1. CD4+ helper T cells 
As the name suggests, CD4+ helper T (Th) cells help to regulate or assist other white 
blood cells such as B cells, macrophages or CD8+ T cells in immunological processes. 
Depending on the type of infection, an effective CD4+ helper T cell response requires 
differentiation into one of the different CD4+ helper T cell subsets (Iwasaki and 
Medzhitov, 2010), which are characterised by different cytokines signatures (Figure 
1.4).  
 
1.2.4.2. CD8+ cytotoxic T cells 
In contrast to CD4+ helper T cells, the role of CD8+ cytotoxic T cells is to directly 
eliminate any cells infected with invading pathogens, such as viruses, bacteria or 
protozoal parasites. In addition, CD8+ T cells are also implicated in the removal of 
cancer cells, allografts from transplants and the clearance of senescent cells. After 
activation, CD8+ T cells undergo much more extensive proliferation than CD4+ cells 
(Foulds et al., 2002). Following activation, CD8+ T cells upregulate the inflammatory 




to the site of infection (Groom and Luster, 2011; Hancock et al., 2002; Hokeness et 
al., 2007). Upon antigen recognition on the surface of a target cell, CD8+ T cells act 
by the calcium dependent release of specialised preformed cytolytic granules 
containing the pore-forming perforin and granzymes. Perforin polymerises to form 
transmembrane pores in the target cell membrane, allowing the entry of granzymes 
into the cytoplasm of the target cell, which trigger the caspase cascade and 
subsequent cell apoptosis (Berke, 1995). To a lesser extent, apoptosis can be induced 
via a second mechanism that involves the binding of Fas on the surface of target cells 
and Fas ligand, which is present on the membrane of activated CD8+ T cells. This Fas 
cell-surface interaction results in caspase activation, which consequently induces 
apoptosis in the target cells (Holler et al., 2003; Krammer, 2000; Rouvier et al., 1993). 
In addition to their apoptotic effects, CD8+ T cells also release pro-inflammatory 
cytokines such as IFN-γ and TNF-α, which contribute to host defence (Martin et al., 
1996; Shresta et al., 1998). For example, viral replication can be directly inhibited by 
IFN- (Kang et al., 2018). 
 
1.2.5. T cell activation 
T cells only recognise foreign antigens that are presented to them on the surface of 
antigen presenting cells (APCs), such as DCs, from the innate immune system. TCR 
signalling alone results in anergy, a non-responsive state in which T cells are unable 
to respond (Alberts et al., 2002). Therefore, in order to become activated, T cells 
require three kinds of signals. Signal 1 is provided when the antigen-MHC complex 




1 is also associated with a complex of invariant transmembrane proteins known as 
CD3 and the CD4 or CD8 co-receptors, which also bind to parts of the same class II or 
class I MHC, respectively (Alberts et al., 2002). Signal 2 is provided by co-stimulation 
of other cell surface receptors such as CD28, which recognise co-stimulatory proteins 
known as B7 proteins on the surface of the presenting cell. Finally, signal 3 is provided 
by the secretion of inflammatory cytokines (Figure 1.5). Successful activation 
stimulates the T cell to undergo mass proliferation, a process known as clonal 
expansion, and differentiate into an effector cell.  
 
 
Figure 1.4: CD4+ Helper T cell subsets 
Differentiation of helper T cell subsets is mediated by cytokines and co-stimulatory 






Figure 1.5: T cell activation 
T cell activation requires three signals from APCs. Signal 1 is generated via TCR signalling, 
which involves the antigen-MHC Class I/II complex, CD3 and CD4 or CD8 depending on MHC 
Class. Alone, signal 1 is not sufficient to activate a T cell response. T cell activation also 
requires signal 2, a co-stimulatory signal involving other cell surface receptors such as CD28 
which recognise B7 proteins (CD80 and CD86) on the surface of APCs. Signal 3 is produced 
by the secretion of cytokines such as IL-2, IL-12 and IFN-. 
 
1.2.6. T cell contraction and memory formation 
Despite serving different immune functions, following successful elimination of an 
infection, both CD4+ and CD8+ T cells undergo contraction of the majority of the T cell 
population (>90%), leaving the remaining small percentage to mature into memory 




selection process is not entirely random as memory cell potential is not inherited 
equally by all effector cells. Instead, some T cells are intrinsically more able than 
others to persist and populate the memory T cell pool. Although not exclusive criteria 
for memory formation, increased expression of CD27 and IL7-Rα and decreased 
expression of killer cell lectin-like receptor in the well characterised model systems 
of lymphocytic choriomeningitis virus (LCMV) or Listeria monocytogenes infection, 
have been shown to predispose for memory precursor cells in CD8+ T cells (Joshi et 
al., 2007). Both CD4+ and CD8+ memory T cells are maintained for long-term survival 
in an antigen independent manner mainly through the actions of IL-7 and IL-15 (Surh 
and Sprent, 2008). This ability to generate immunological memory is invaluable as it 
provides the host with a set of cells that can mount a much faster and stronger 
immune response upon secondary infection.  
 
Two broad subsets of memory T cell exist: central memory T cells (CM) and effector 
memory T cells (EM) (Sallusto et al., 1999). Functionally, CM cells produce IL-2 and 
tend to mount a much more robust response upon second encounter, whereas CD4+ 
and CD8+ EM cells are immediate producers of IFN-γ and TNF-α or cytotoxic proteins. 
Although the exact path of differentiation remains under debate, the general 
assumption is that T cells progress from naïve T cells through to CM, then EM, before 
finally becoming terminally differentiated effector memory T cells. Expression of 
various surface markers are used to identify human T cells in these different 
differentiation states (Table 1). For example, naïve T cells express CD45RA, however, 




differentiated T cells regain expression of CD45RA, therefore these are known as 
effector memory T cells that re-express CD45RA (EMRA) (Hamann et al., 1997, 1999) 
(Table 1).  
 
Surface Marker Naïve CM EM EMRA 
CD45RA + - - + 
CD45RO - + + - 
CCR7 + + - - 
CD27 + + - - 
CD28 + + + - 
CD62L + + - - 
CD95 - + + + 
KLRG1 - - + + 
CD57 - - - + 
 
Table 1.2: The phenotype of T cell subsets [Adapted from (Akbar et al., 2004; Kaech 
and Cui, 2012)].  
 
1.2.7. T cell senescence and ageing 
Immunosenescence affects all aspects of our immune system, however, much of the 
deterioration in the protective immune response has been attributed to defective T 
cell immunity (Nikolich-Zugich, 2005). This is the result of a decline in naïve T cell 
output due to thymic involution and the accumulation of EMRA T cells, which display 




1.2.7.1. Thymic involution 
The thymus is a vital primary lymphoid organ that provides a continuous, steady 
supply of naïve T cells, which is essential for preserving the diverse repertoire of naïve 
T cells responsible for tackling the broad range of new pathogens we encounter 
throughout life. Despite having such an important role, in humans the thymic 
epithelial space is replaced by fat as we age, a process known as thymic involution 
(Henry, 1967). Consequently, thymic output of new naïve T cells declines dramatically 
until it eventually reaches a point, usually around the age of 60, where there is no 
longer an effective naïve T cells output (Lynch et al., 2009; Taub and Longo, 2005). 
Consequently, new T cells must either be generated at extra thymic sites or be 
clonally expanded from pre-existing T cells. This depleted pool of naïve T cells means 
that older individuals are less equipped to fight off any new infections they may 
encounter. 
 
1.2.7.2. EMRA accumulation 
During primary infection, CD8+ T cells upregulate the expression of telomerase, 
resulting in an increase in telomere length (Hathcock et al., 2003; Maini et al., 1999; 
Plunkett et al., 2001). This upregulation ensures that antigen specific T cells that go 
on to form the memory pool retain their proliferative capacity. Throughout life 
subsequent re-encounter with antigen induces further rounds of clonal expansion 
and contraction of the specific memory T cell populations (Akbar et al., 1993). The 
ability to upregulate telomerase decreases after repeated stimulation, consequently 




chronic viral infections such as cytomegalovirus (CMV) and human immunodeficiency 
virus (HIV), which is known to cause large clonal populations of T cells with 
significantly reduced telomeres (Effros et al., 1996; Hodes et al., 2002; Monteiro et 
al., 1996). However, unlike in somatic cells, the role of telomere erosion in T cells is 
more complex, as it has been shown that although both CD8+ and CD4+ EMRA T cells 
have shorter telomeres than naïve T cells, they do not have the shortest telomeres 
when compared to other memory subsets (Di Mitri et al., 2011; Riddell et al., 2015), 
suggesting that non-telomeric senescent drivers are at play.  
 
EMRA T cells lose the expression of the co-stimulatory molecule CD28, which is 
essential for the activation of the NF-κB pathway (Schmitz et al., 2003), IL-2 
transcription and glucose metabolism (Thompson et al., 1986). Furthermore, EMRA 
T cells display many characteristics of cellular senescence such as a reduction in 
proliferative capacity (Erickson et al., 1998), defective mitochondrial function and 
elevated levels of ROS and p38 MAPK (Henson et al., 2014). Despite these senescent 
characteristics, EMRA T cells remain functionally active as they can secrete high levels 
of TNF-α and IFN- (Henson et al., 2014) and express high levels of perforin and 
granzyme B, indicating that they maintain potent cytotoxic activity (Plunkett et al., 
2014). Moreover, CD8+ EMRA T cells begin to express a variety of NK receptors 
suggesting a possible repurposing of these cells (Pereira et al., 2019; Tarazona et al., 
2001). Consequently, they are distinct from functionally exhausted CD8+ T cells, 
which have proliferative defects but also have lost the ability to secrete cytokines 




1.3. Metabolic regulation of T cells  
Cell metabolism is a vital regulator of T cell function and fate. As cells are stimulated 
to grow, proliferate or even die, their metabolic requirements change in order for 
cell metabolism to match these demands. In fact, pathways that regulate T cell 
function and metabolism are closely linked. For example, during activation of effector 
T cells, signals from CD28 and IL-2 induce the PI3K-dependent activation of AKT 
(Frauwirth et al., 2002; Wieman et al., 2007; van der Windt and Pearce, 2012). 
Activated AKT promotes the mTOR pathway and ultimately results in a shift toward 
glycolysis as the primary metabolic program even in the presence of sufficient oxygen 
(Edinger, 2002; Elstrom et al., 2004; Rathmell et al., 2003) - a process known as 
aerobic glycolysis or Warburg metabolism (Figure 1.6). This is not surprising as a 
metabolic program such as glycolysis, which prioritises rapid biosynthesis over 
efficient energy/ATP production, is much more likely to meet the metabolic needs of 
activated T cells that are rapidly proliferating.  
 
Unlike their effector counterparts, memory T cells do not primarily use aerobic 
glycolysis. Instead they rely more on OXPHOS and mitochondrial fatty acid oxidation 
(FAO) for their development and persistence (Figure 1.6). Memory T cells also have 
increased mitochondrial mass, allowing them to use a diverse range of substrates for 







Figure 1.6: Metabolic pathways that support T cells 
During OXPHOS electrons generated from the TCA cycle (blue) are transferred along the 
electron transport chain (ETC) in redox reactions. These reactions release energy, which is 
used to generate ATP. Glycolysis involves the enzymatic breakdown of glucose (red). In 
anaerobic conditions, glycolysis produces lactate, whereas in aerobic conditions it produces 
pyruvate, which is then converted to acetyl-CoA. Other substrates such as glutamine via 
glutaminolysis or fatty acids (FA) via fatty acid oxidation (FAO, yellow) can be metabolised in 
the TCA cycle to fuel OXPHOS. Furthermore, these biochemical pathways can also provide 
metabolic precursors for biosynthesis. For example, intermediates from glucose catabolism 
during glycolysis can enter the pentose phosphate pathway and the serine biosynthesis 
pathway to fuel the production of nucleotides and amino acids. Finally, citrate from the TCA 
cycle can be shuttled from the mitochondria and converted to acetyl-CoA for fatty acid 




1.3.1. Alterations in T cell metabolism with senescence 
Senescent T cells also display a unique metabolic signature. Unlike other memory 
subsets, ex vivo derived CD8+ EMRA T cells utilise anaerobic glycolysis instead of 
OXPHOS (Henson et al., 2014). Interestingly, this is similar to what has been shown 
in senescent fibroblast cells generated by replicative senescent and radiation, which 
shift their energy production to glycolysis (James et al., 2015). Despite a lack of 
proliferation, senescent T cells are highly active cells that display effector functions 
and secrete large amounts of cytokines and maintain potent cytotoxic activity 
(Henson et al., 2012). Consequently, their reliance on glycolysis ensures rapid 
biosynthesis to meet the high metabolic demands of these cells. Senescent CD8+ T 
cells also exhibit mitochondrial dysfunction, which is characterised by a reduced 
mitochondrial content. Moreover, the remaining mitochondria are large and 
dysfunctional resulting in a substantially decreased mitochondrial spare respiratory 
capacity (SRC). These mitochondrial alterations may provide an explanation for their 
dependence on anaerobic glycolysis (Henson et al., 2014) and their lack of 
mitochondrial biogenesis is likely due to the failure of senescent CD8+ T cells to 
activate mTORC1 – a central integrator of immune signalling and cell metabolism 
(Henson et al., 2014).  
 
1.4. The relationship between senescent T cells and inflammatory diseases 
In addition to their role in ageing, there is an ever growing appreciation that 
senescent T cells also play a role in many chronic inflammatory and metabolic 




rheumatoid arthritis (RA) (Weyand et al., 2014). This is not surprising as senescent T 
cells produce high levels of IFN- and TNF-α (Henson et al., 2014) and secrete a SASP 
meaning they are highly pro-inflammatory (Callender, Carroll, Beal, et al., 2018).  
 
1.4.1. Senescence and Type 2 diabetes 
Diabetes, in particular type 2 diabetes (T2D), is an increasing risk to human health. 
Globally, diabetes affects 422 million people, which equates to 8.5% of the adult 
population and is almost double the 4.7% of adults that were affected in 1980 (World 
Health Organization, 2016). Around 90% of these diabetes cases are due to T2D 
(World Health Organization, 2016). This rise in prevalence reflects an increase in 
associated risk factors of T2D, such as obesity and an ageing population. T2D is a 
multifactorial disease caused by insulin resistance and characterised by a 
combination of metabolic imbalances and chronic low-grade inflammation. 
Consequently, T2D was chosen as a model to investigate the relationship between 
inflammation, metabolism and T cell senescence. Senescence has previously been 
implicated in the pathogenesis of T2D. With senescent cell burden being shown to 
increase in tissues that undergo diabetes induced damage, such as the kidneys 
(Verzola et al., 2008) and pancreas (Sone and Kagawa, 2005). Interestingly, 
CD4+CD28- T cells, which are a late stage differentiated population, have already been 
reported to accumulate in T2D (Giubilato et al., 2011). A similar finding was observed 
in obese mice, where senescent CD4+ T cells were found to accumulate in the visceral 
adipose tissue  (VAT) and cause the induction of chronic VAT inflammation 




shown to increase the risk of hyperglycaemia in humans, highlighting a potential role 
for this subset in the pathogenesis of T2D (Lee et al., 2019). Collectively, these studies 
show an association between T2D and terminally differentiated T cells; however, a 
full assessment of T cell senescence in T2D has not been conducted.  
 
1.5. Rationale and aims 
The role of senescent T cells in ageing is well established (Chou and Effros, 2013). 
However, the heterogeneity that exists within the EMRA T cell population and the 
reason behind why the CD8+ and CD4+ lineages have different susceptibilities to 
senescence is still not understood. Furthermore, the generation of senescent T cells 
during inflammation and metabolic overload has not been properly investigated.  
 
1.5.1. Specific aims 
• To characterise the senescent properties of CD8+ and CD4+ T cells with a 
particular focus on the heterogeneity that lies within these senescent 
populations.  
• To investigate the metabolic properties of senescent T cells in the CD8+ and CD4+ 
T lineages. 
• To compare the senescent properties of CD8+ T cells isolated from people living 
with T2D and healthy age-matched control donors.  





Chapter two: Materials and Methods 
2.1. Ethics and blood donor recruitment 
Ethics for blood collection were approved by the NRES Committee North East (REC 
reference: 16/NE/0073) and all subjects provided written informed consent. Healthy 
volunteers (Age range: 20 – 75 years, median: 40 years, n = 45) were individuals who 
had not had an infection or immunisation within the last month, no known 
immunodeficiency, and had not received any other immunosuppressive medications 
within the last 6 months. People living with T2D (Age range: 50 – 77 years, median: 
64 years, n = 52) were recruited by Prof Graham Hitman, Prof Sarah Finer, and Dr Gill 
Hood through the Diabetes Alliance for Research in England (DARE) database.  
 
T2D donors were individuals that were currently living with T2D and aged > 18 years 
(preference was given to individuals between 50 – 60 years). Donors were excluded 
from the study if they were unable to provide written informed consent, had suffered 
from an infection or immunisation in the month prior to blood collection, had any 
known immunodeficiencies or a history of chemotherapy/radiotherapy, had received 
any immunosuppressive medications within the last 6 months, had a significant co-
morbidity (renal failure, heart failure etc), had a known bleeding condition or were 
on warfarin medication and had a history of neoplasm in the last 10 years. In addition 
to a blood sample, the donors age, gender, length of time since T2D diagnosis and 





2.2. Peripheral blood mononuclear cell (PBMC) isolation and serum collection 
To isolate PBMCs, blood was collected in heparinised vacutainers (BD Biosciences), 
diluted in phosphate buffered saline (PBS) (Sigma-Aldrich) then layered on top of 15 
mL of Ficoll-paque™ Plus (GE Healthcare) in a 50 mL falcon tube. Layered samples 
were centrifuged at 2,000 rpm for 20 minutes without any brake. PBMCs were then 
carefully aspirated and transferred to a new 50 mL falcon, mixed with PBS and 
centrifuged at 1,800 rpm for 15 minutes. The supernatant was then removed, and 
the cell pellet was resuspended in PBS before being centrifuged for a final time at 
1,800 rpm for 10 minutes. Following isolation, PBMCs were stained with Trypan Blue 
Solution (Sigma-Aldrich), counted using a haemocytometer and then either used 
immediately or cryopreserved at -80°C in freezing medium (fetal calf serum (FCS) 
with 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich)) for future use. All PBMCs were 
cultured in RPMI media supplemented with 10% FCS, 1 mM L-glutamine and 1 mM 
penicillin and streptomycin (All Sigma-Aldrich). For serum collection, blood was 
collected in serum blood tubes (BD Biosciences) and centrifuged at 1,800 rpm for 10 
minutes. Following centrifugation, the top serum layer was carefully removed and 
either used immediately or cryopreserved at -80°C. 
 
2.3. Jurkat cell culture 
Jurkat cells (clone E6-1 ATCC), an immortalised cell line derived from an acute T cell 
leukaemia, were cultured using RPMI-1640 media supplemented with 10% FCS, 1 
mM L-glutamine and 1 mM penicillin and streptomycin. Cells were split and media 
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CCR7 G043H7 Biolegend PE-Cy7 1:25 Flow cytometry 
KLRG1 MAFA Miltenyi Biotec PE 1:20 Flow cytometry 
CD57 HNK-1 Biolegend APC 1:20 Flow cytometry 
Ki-67 Ki-67 Biolegend PE 1:25 Flow cytometry 










Flow cytometry & 
Western blot 
CD36 5-271 Biolegend FITC 1:20 Flow cytometry 




unconjugated 1:50 Flow cytometry 
GLUT-1 202915 R&D systems PE 1:10 Flow cytometry 
CD107a H4A-3 Biolegend AF647 1:25 Flow cytometry 
pAMPK T172 – 40H9 Cell Signaling - 1:50 Flow cytometry 
PGC1 3G6 Cell Signaling  - 1:50 
Flow cytometry & 
Western blot 
CHEK1 E250 Abcam unconjugated 1:2 Immunoprecipitation 
TOM20 FL-145 Santa Cruz - 1:100 Confocal microscopy 
Goat to 
Rb 
- Abcam AF488 1:1000 
Flow cytometry & 
Confocal microscopy 
 




2.5. Flow cytometry analysis 
Surface staining and intracellular staining were analysed by flow cytometry. 
Unstained, single colour controls and fluorescence minus one samples were 
prepared for control purposes. All samples were acquired on an LSR Fortessa (BD 
Biosciences) equipped with four lasers: 488 nm blue laser, 561 nm yellow green laser, 
641 nm red laser and 405 nm violet laser and data was analysed using FlowJo 
software. 
 
2.5.1. Surface marker staining for flow cytometry 
Flow cytometric analysis was performed on approximately 1 x 106 PBMCs per sample. 
Cells were incubated in the dark with the Zombie_NIR live/dead stain (Biolegend) and 
appropriate antibodies (Table 2.1) in Brilliant Violet (BV) buffer (BD Biosciences) for 
15 minutes at room temperature. Cells were washed in 200 µL of BV buffer, 
centrifuged at 1,800 rpm for 5 minutes and then fixed in 2% paraformaldehyde (PFA) 
(Sigma-Aldrich) in PBS prior to analysis.  
 
2.5.2. Intracellular staining for flow cytometry 
Approximately 1 x 106 PBMCs per sample were surface stained with appropriate 
antibodies as described above. The FIX & PERM® Cell Permeablilisation Kit (Life 
Technologies) was used to enable intracellular staining. Immediately after surface 
staining, cells were incubated with 100 µL of Reagent A (Fixation Medium) for 15 
minutes in the dark at room temperature. Cells were then washed in PBS, centrifuged 




Medium) plus 10% goat serum and recommended volume of primary intracellular 
antibody. Cells were incubated for 20 minutes in the dark at room temperature then 
washed in PBS at 1,800 rpm for 5 minutes before secondary antibody was added and 
incubated for 20-minutes in the dark at room temperature. Finally, cells were washed 
in PBS and centrifuged at 1,800 rpm for 5 minutes and resuspended in 100 µL 2% PFA 
in PBS. Samples were either analysed immediately or stored overnight at 4°C. The 
Foxp3 Transcription Factor Staining Buffer Kit (Biolegend) was used for staining 
transcription factors and nuclear proteins. Following surface staining cells were 
washed in PBS and then incubated with 1 mL of the FOXP3 Fix/Perm buffer (4X) for 
20 minutes in the dark at room temperature. Cells were then washed in PBS and 
incubated with 1 mL of the FOXP3 Perm buffer (10X) for 15 minutes in the dark at 
room temperature. Cells were washed again and incubated with 50 µL of FOXP3 Perm 
buffer (10X) and appropriate amount of the antibody being used for 30 minutes in 
the dark and room temperature. The cells were then washed for a final time in PBS, 
centrifuged at 1,800 rpm for 5 minutes and resuspended in 100 µL 2% PFA in PBS. 
Samples were either analysed immediately or stored overnight at 4°C. 
 
2.5.3. Assessment of cytotoxicity via flow cytometry  
To assess cytotoxicity, approximately 1 x 106 PBMCs were stimulated with 1 µg/µL of 
anti-CD3 (OKT3) and incubated with CD107a in complete RPMI-1640 media for 45 
minutes at 37°C. Then 100 µM of monensin (Biolegend) (Sigma-Aldrich) was added 
and the cells were incubated for a further 4 hours and 15 minutes at 37°C. Next, cells 




washed in PBS, centrifuged at 1,800 rpm for 5 minutes and resuspended in 100 µL 
2% PFA in PBS ready to either be analysed immediately or stored overnight at 4°C.  
 
2.6. Magnetic bead sorting of CD4+ and CD8+ T cells 
PBMCs were isolated as described in section 2.2 and centrifuged at 1,800 rpm 
following cell counting and resuspended in 80 µL MACS buffer (1x PBS supplemented 
with 0.5% BSA and 2mM Ethylenediaminetetraacetic acid (EDTA)) per 107 cells and 
20 µL of either anti-CD4+ or anti-CD8+ conjugated MicroBeads per 107 cells. Samples 
were gently mixed and incubated at 4°C for 15 minutes. Following incubation, 
samples were washed with 3 mL of MACS buffer and centrifuged at 1,800 rpm for 5 
minutes. In preparation for magnetic separation, dependent on cell number either 
MS or LS columns (Miltenyi Biotec) were placed on the separator and pre-washed 
with either 0.5 mL or 3 mL MACS buffer respectively. Once washed, samples were 
resuspended in 0.5 mL or 3 mL of MACS buffer and added to the columns.  Flow 
through was collected in 15 mL falcons below the column. Once all the sample had 
passed through, the columns were washed with 3 x 0.5 mL or 3 mL of MACS buffer. 
Following the washes, columns were then removed from the separator and placed in 
a new 15 mL falcon. 0.5 mL or 3 mL of MACS buffer was then added to the columns 
and positively labelled cells were removed using the column plunger provided. Cells 
were then washed with 2 mL of MACS buffer per 107 cells, centrifuged at 1,800 rpm 






2.7 Flow cytometry cell sorting of T cell subsets 
CD4+ or CD8+ T cells were isolated using magnetic sorting described above. T cell 
subsets were surface stained with CD27 and CD45RA as describe in section 2.5.1 and 
then sorted into naive, CM, EM and EMRA subsets on a BD FACSAria™ Fusion 
equipped with three lasers: 488 nm blue laser, 641 nm red laser and 405 nm violet 
laser. Following isolation, subsets were then used for downstream experiments such 
as RNA or protein extraction, siRNA electroporation and metabolic seahorse assays. 
 
2.8. Mitochondrial measurements 
For mitochondrial mass, PBMCs were incubated with 100 nM MitoTracker Green FM 
(Invitrogen™) for 30 minutes at 37°C, 5% CO2. Mitochondrial membrane potential 
(MMP) was investigated using Tetramethylrhodamine (TMRE) (ThermoFisher 
Scientific) 2 µM TMRE was incubated with PBMCs for 30 minutes at 37°C, 5% CO2. 
MitoSox Red (Invitrogen™) was used to assess mitochondrial ROS production; PBMCs 
were incubated with 5 µM MitoSox for 30 minutes at 37°C, 5% CO2. Following 
mitochondrial staining, samples were surface stained as described in section 2.5.1 
and then left unfixed and immediately analysed on an LSR Fortessa (BD Biosciences). 
 
2.8.1. Confocal microscopy analysis of mitochondria  
To assess mitochondrial morphology, Jurkat cells were plated onto 12 well 
microscope slides at a density of 0.05 x 106 per well. Cells were fixed and permed 
using the FIX & PERM® Cell Permeablilisation Kit to enable intracellular labelling. Cells 




temperature. Cells were then washed in PBS x 3 and resuspended in 50 µL of Reagent 
B (Permeablisaton Medium) plus 10% goat serum and Tom20. Cells were incubated 
for 30 minutes at room temperature then washed in PBS before the secondary goat 
to Rb antibody was added and incubated for a further 20 minutes in the dark at room 
temperature. Next, cells were washed in PBS and incubated with 4′,6-diamidino-2-
phenylindole (DAPI) (ThermoFisher Scientific) for 10 minutes at room temperature in 
the dark. Finally, cells were washed with PBS then fixed with 100 µL 2% PFA in PBS. 
Samples were imaged on a Zeiss LSM 880 confocal microscope with a X 63 oil-
immersion objective lens. Excitation was at 488 nm from an argon-ion laser. 
Fluorescence detection was in the green; and UV; 405 nm channel. Quantification of 
image data was performed by measuring the intensity of the 500 – 570 nm channel 
using ZEN-imaging. Imaris Image Analysis software was used determine 
mitochondrial volume through surface 3D rendering of Z-stack images. 
 
2.9. Live cell metabolic assays 
Metabolic assays were measured in whole CD4+/CD8+ T cells and/or in CD4+/CD8+ 
CD27/CD45RA FACS sorted subsets. Seahorse sensor cartridges were incubated at 
37°C in a non-CO2 incubator overnight with Seahorse XF Calibrant pH 7.4 (Agilent) to 
rehydrate the sensor probes. All metabolic assays were performed with a cell density 
of 0.25 x 106 per well, attached using of 22.4 µg/mL of Cell-Tak (Corning®) and 
measured using a Seahorse XFe96 Analyser (Agilent). Cells were stimulated with 1 





2.9.1. Cell Mito Stress Test 
The Cell Mito Stress Test (Agilent) was used to assess mitochondrial function and 
OXPHOS. The assay was performed in RPMI-1640 buffer without phenol red and 
carbonate buffer (Sigma-Aldrich) containing 25 mM glucose, 2 mM L-glutamine and 
1 mM pyruvate with a pH of 7.4. The stress test was performed using 1 µM 
Oligomycin, 1.5 µM, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), 
100 nM rotenone, and 1 µM antimycin A (Agilent) (Figure 2.1). Metabolic 
measurements were calculated using the equations shown in Table 2.2.  
 
Figure 2.1: Schematic diagram of the mitochondria inhibitors used in the Cell Mito 








Non-mitochondrial respiration Measurements after Rotenone/Antimycin A injection 
Basal respiration (Measurements before first injection) –  
(Non-mitochondrial respiration) 
Proton leak (Measurements after Oligomycin injection) –  
(Non-mitochondrial respiration) 
ATP production (Measurements before Oligomycin injection) – 
(Measurements after Oligomycin injection) 
Maximal respiration (Measurements after FCCP injection) –  
(Non-mitochondrial respiration) 
Spare respiratory capacity (Maximal respiration) – (Basal respiration) 
 
Table 2.2: Seahorse XF Cell Mito Stress Test parameter equations 
 
2.9.2. Fatty acid oxidation 
The Seahorse XF Palmitate assay (Agilent) was used to determine FAO. Cells were 
incubated overnight in substrate limited (DMEM (Gibco), 0.5 mM glucose, 1 mM L-
glutamine, 0.5 mM carnitine, and 1% FCS). 45 minutes prior to the assay cells were 
transferred to warm Krebs-Henseleit KH Buffer (KHB) (111 mM NaCL, 4.7mM KCL, 
1.25 mM CaCl2, 2 mM MgSO4, 1.2 mM NaH2PO4) supplemented with 2.5 mM glucose, 
0.5 mM carnitine, 5 mM HEPES adjusted to pH 7.4. Then, 15 minutes prior to the 
assay 40 µM Etoximir was added to selected groups. Finally, the cells were provided 
with Palmitate:BSA (Aglient) as a substrate and a Cell Mito Stress Test as described 




2.10. Nutrient uptake experiments 
Approximately 1 x 106 PBMCs per condition were stimulated for either 1 hour or 
overnight at 37°C with 1 µg/µL of anti-CD3 in complete RPMI-1640 media. For glucose 
uptake, PBMCS were washed in PBS and centrifuged at 1,800 rpm for 5 minutes then 
resuspended in glucose free media for 15 to 30 minutes. 100 µM of the fluorescent 
glucose analogue 2-NBDG (Invitrogen™) was then added and the PBMCs were 
incubated in the dark for 30 minutes. Next, the cells were washed in PBS, centrifuged 
at 1,800 rpm for 5 minutes, and surface stained with phenotyping antibodies as 
described in section 2.5.1. Cells were then washed for a final time, resuspended in 
PBS and taken immediately to the flow cytometer for analysis. To measure lipid 
uptake stimulated PBMCs were incubated with the 1 nM of the fluorescent palmitate 
analogue BODIPY FL C16 (Invitrogen™) and incubated in the dark for 10 minutes. Cells 
were then washed in PBS, centrifuged at 1,800 rpm for 5 minutes and surface stained 
before being analysed by flow cytometry. 
 
2.11. Protein extraction and western blotting 
Cells were centrifuged at 1,800 rpm for 5 minutes, then the cell pellet was 
resuspended in approximately 200 µL of RIPA buffer plus inhibitors (protease: 
complete mini Roche; 11836153001, and phosphatases: cocktail set II Calbiochem; 
524625). Samples were kept on ice for 15 minutes and the centrifuged at 4°C for 15 





Cell lysates were fractionated by SDS-polyacrylamide electrophoresis before being 
transferred onto nitrocellulose membranes. Membranes were then blocked with 
blocking buffer (5% milk power, 0.05% Tween-20 in PBS) for 1 hour at room 
temperature on a shaker. Primary antibody was diluted accordingly in primary 
antibody buffer (5% milk/BSA, 0.05% Tween-20 in PBS) and then incubated overnight 
at 4°C on a shaker. Membranes were then washed three times in wash buffer (PBS + 
0.05% Tween-20), and secondary antibody was added in the blocking buffer then 
incubated for 30 minutes to 1 hour at room temperature on a shaker before being 
washed a further three times. The protein was detected via chemiluminescence, by 
means of the ECL system (GE Healthcare). 
 
2.12. Immunoprecipitation 
For immunoprecipitation experiments the Chk1 antibody was incubated with Red 
Protein G Affinity Gel (Sigma-Aldrich; E3403) for 1 hour at 4°C on a shaker to allow 
the antibody to bind to the beads. Cell lysates were prepared as described above and 
then incubated with the antibody-bead mix overnight at 4°C on a shaker. The 
following morning, samples were centrifuged, and the supernatant was discarded 
leaving only the proteins able to bind to Chk1. SDS-polyacrylamide electrophoresis 
and western blotting of GATA binding protein 3 (GATA3) and peroxisome proliferator 
activated receptor gamma coactivator 1-alpha (PGC1) was then carried performed 




2.13. siRNA knockdown 
GATA-3 and scrambled siRNA (Table 2.3) were dissolved to a final concentration of 
10 µM in electroporation buffer (15 mM NAH2PO4, 35 mM NA2HPO4, 5 mM KCl, 10 
mM MGCl2, 11 mM glucose, 100 mM NACl, 20 mM HEPES, 15.9 mM NaOH in Milli-Q 
H2O). For each transfection cells were centrifuged at 1,800 rpm for 5 minutes and 
resuspended in 100 µL of the siRNA solution and transferred to an electroporation 
cuvette. Cells were electroporated using program T-023 on an Amaxa 
Nucleofector (Lonza Bioscience) and then left to recover for 24 to 48 hours in fresh 
RPMI-1640 media supplemented with 10% FCS, 1 mM L-glutamine and 1 mM 




siRNA Sequence Conjugate 
GATA-3 5’-/5Alex647N/UAG GCG AAU CAU UUG UUC AAA-3’ AF647 










2.14. Cellular Senescence RT2 Profiler PCR Arrays 
Unstimulated CD8+ EMRA T cells from T2D and healthy age-matched control donors 
were isolated using MACS sorting for CD8+ T cells and then FACs sorting using 
CD27/CD45RA for EMRA isolation as described above. RNA was extracted and pre-
amplified and then ran on the Cellular Senescence RT2 Profiler PCR Arrays (PAHS-
050Z) as described below. 
 
2.14.1. RNA extraction  
Total RNA was extracted using the RNAeasy Micro Kit (217084) according to the 
manufacturer’s protocol. First, cells were pelleted, resuspended in 350 µL of RTL 
buffer supplemented with 10% β-mecaptoethanol. 350 µL of 70% ethanol was added 
to the homogenised lysate and the total 700 µL was transferred into an RNeasy spin 
column placed in a 2 mL collection tube. The sample was centrifuged at 10,000 rpm 
for 15 seconds, and then flow through was discarded. 700 µL of RW1 buffer was 
loaded into the spin column, centrifuged at 10,000 rpm for 15 seconds, and then flow 
through was discarded. 500 µL of RPE buffer supplemented with ethanol was then 
added to the spin column and again centrifuged at 10,000 rpm for 15 seconds to 
wash the spin column membrane, afterwards flow through was discarded. An 
additional 500 µL of RPE buffer was added to the spin column and centrifuged at 
10,000 rpm for 2 minutes. Following the second wash with RPE buffer both the flow 
through and 2 mL collection tube were discarded. Spin columns were placed in fresh 
2 mL collection tubes and centrifuged at full speed for 1 minute to eliminate any 




columns were placed in fresh 1.5 mL eppendorf tubes. 14 µL of RNase-free water was 
directly added to the spin column membrane and centrifuged at 10,000 rpm for 1 
minute to elute the RNA. RNA quality and quantity were measured by 
spectrophotometry (Nano drop ND-1000). RNA was then frozen at -80⁰C until ready 
to use for the RT2 profiler arrays. 
 
2.14.2. cDNA synthesis and pre-amplication of RNA samples 
Due to the low cell numbers and therefore low concentration of RNA the RT2 PreAMP 
cDNA Synthesis Kit (330451) and RT2 PreAMP Pathway Primer Mix (330241) were 
used to for preamplification of the RNA samples. First, cells were subjected to 
genomic DNA elimination by incubating the RNA samples with 2 µL of Buffer GE and 
RNase-free water in a final volume of 10 µL for 5 minutes at 42⁰C before being placed 
immediately on ice for at least 1 minute. Next the samples were incubated with 10 
µL of reverse transcription mix (Table 2.4) to generate a cDNA target template. 
 
Following gentle mixing samples were incubated at 42⁰C for exactly 20 minutes then 
immediately stopped by incubating at 95⁰C for 5 minutes before being placed on ice. 
5 µL of the cDNA synthesis reactions were gently mixed with 20 µL of pre-
amplification mix (Table 2.5) and placed into the real-time cycler to undergo pre-






Component Volume for 1 sample 
5x Buffer BC3 4 µL 
Control P2 1 µL 
cDNA Synthesis Enzyme Mix 1 µL 
RNase Inhibitor 1 µL 
RNase-free water 3 µL 
Total volume 10 µL 
 




Component Volume for 1 sample 
RT2 PreAMP PCR Mastermix 12.5 µL 
RT2 PreAMP Pathway Primer Mix 7.5 µL 
Total volume 20 µL 
 








Cycles Duration Temperature 
1 10 minutes 95⁰C 




Hold  4⁰C 
 
Table 2.6: Cycling conditions for pre-amplification of cDNA 
 
After cycling 2 µL of Side Reaction Reducer was added to each sample and incubated 
at 37⁰C for 15 minutes followed by heat inactivation at 95⁰C for 5 minutes. 
Immediately after 85 µL of nuclease-free waster was added and mixed with the 
samples before they were either placed on ice or stored at -20⁰C overnight. 
 
2.14.3. Real-Time PCR using RT2 Profiler PCR Arrays 
Once the PCR components mix (Table 2.7) was prepared, 25 µL was dispensed into 
each well of the 96 well plate. The plate was then carefully sealed with the optical 
adhesive film, centrifuged for 1 minute at 1000 g at room temperature to remove 








Component Volume for 96-well plate 
2x RT2 SYBR Green MasterMix 1275 µL 
Pre-amplification reaction (from previous steps) 102 µL 
RNase-free water 1173 µL 
Total volume 2550 µL 
 




Cycles Duration Temperature 
1 10 minutes 95⁰C 





Table 2.8: Cyclin conditions for qPCR data collection 
 
2.14.4. RT2 PCR array data analysis  
Following the qPCR run CT values for all wells were exported to a blank excel 
spreadsheet and imported onto the Qiagen data analysis web portal at 
http://dataanalysis.qiagen.com/pcr/arrayanalysis. From this the online software 





2.15. Sera culture experiments 
Sera isolated from T2D patients and healthy age-matched control donors was 
isolated from whole blood as described in sections 2.2. Sera was then incubated at 
56⁰C for 20 minutes to decomplement. PBMCs were isolated from a young donor as 
described in section 2.2 and cultured in either low (5mM) or high glucose (25mM) 
RPMI-1640 media with or without 10% sera from either T2D patients or healthy age-
matched control donors. Flow cytometry staining was carried out on samples at day 
0, 3 and 7 in order to phenotype the samples. 
 
2.16. Cytokine array 
Sera was collected as described in section 2.2 and cytokine levels were measured 
using the Proteome Profiler Human Cytokine Array (R&D Systems; ARY0058). Array 
membranes were first incubated with 2 mL of Array Buffer 4 for 1 hour on a rocking 
platform shaker to block the membranes. At the same time, the samples were 
prepared by adding 200 µL or each sample to 100 µL of Array Buffer 4 and then 
adjusted to a final volume of 1.5 mL using the Array Buffer 5. 15 µL of reconstituted 
Human Cytokine Array Detection Antibody Cocktail was added to each sample and 
left to incubate at room temperature for 1 hour. After 1 hour, Array Buffer 4 was 
aspirated from the membranes and the sample/antibody mixture was added. 
Membranes were incubated overnight at 4⁰C on a rocking platform. The following 
day the membranes were washed with 20 mL 1X Wash Buffer for 10 minutes on a 
rocking platform shaker. This step was repeated twice more before the membranes 




Membranes were then washed three times as described above. Finally, each 
membrane was covered with 1 mL of Chemi Reagent Mix, covered with a plastic 
sheet protector and left to incubate for 1 minute. Following incubation, the 
membranes were blotted to remove excess liquid and then placed in an 
autoradiography film cassette. Membranes were then exposed to X-ray film. Multiple 
exposure times were used (30 seconds – 20 minutes). Later the X-ray films were 
scanned and the mean pixel intensities for each cytokine (Figure 2.2) were calculated 
using image studio software to quantify the results. 
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Figure 2.2: Human Cytokine Array coordinates 
 
2.17. t-SNE analysis 
Following flow cytometry acquisition, CD8+ T cells were gated on healthy, live 
lymphocytes in FlowJo (BD) as described later in section 3.2.1. After gating on the 
population of interest, each sample was exported for t-SNE analysis. t-SNE was run 




2.18. Statistical analysis 
GraphPad Prism was used to create all graphs and statistical analysis. Data are 
presented as mean ± standard error of mean (SEM) of n samples per group. The 







Chapter three: Characterisation of CD8+ and CD4+ EMRA T cells 
3.1. Introduction 
The majority of senescent T cell research has focused on replicative senescence 
(Chou and Effros, 2013); however, many types of premature senescence phenotypes 
have been document in fibroblasts (Kang et al., 2011; Serrano et al., 1997; Toussaint 
et al., 2002). It is therefore likely that other cell types, including T cells, will also be 
susceptible to the induction of premature senescence. Furthermore, the majority of 
T cell senescence has been studied in CD8+ T cells, as CD8+ EMRA T cells are far more 
abundant and undergo more dramatic phenotypic and functional changes (Henson 
et al., 2014). Senescent CD4+ T cells are present but in fewer numbers than their CD8+ 
counterparts. Both CD8+ and CD4+ EMRA T cells lose the expression of co-stimulatory 
molecules CD28 and CD27, although the order in which this occurs differs. CD8+ 
EMRAs lose CD28 expression first whereas the reverse is true for CD4+ EMRAs (Larbi 
and Fulop, 2014). Functionally, CD4+ EMRAs have been shown to acquire cytolytic 
abilities, a quality usually reserved for CD8+ T cells (Nakajima et al., 2002). Despite 
being able to retain some effector function both CD8+ and CD4+ senescent T cells 
have been shown to significantly contribute to T cell dysfunction and the 
deterioration of the immune system in older individuals (Chou and Effros, 2013). 
 
3.1.1. Aim 
The aim of this chapter was to characterise the senescent properties of both CD8+ 
and CD4+ T cells with a particular focus on the heterogeneity that lies within the 




3.2. Utilisation of flow cytometry to identify CD8+ and CD4+ T cells 
Flow cytometry allows in depth analysis of T cell populations. Forward scatter (FSC) 
and side scatter (SSC) FACS plots were used to assess both the size and granularity of 
cells respectively (Figure 3.1A). Lymphocytes formed a tight distinct population away 
from the larger monocytes, smaller red blood cells and any cellular debris (Figure 
3.1A). FSC-area and FSC-height FACS plots were used to eliminate any doublets 
(Figure 3.1B) and gating against a live/dead stain enabled the selection of healthy, 
live lymphocytes (Figure 3.1C). From this either CD8+ or CD4+ T cells were then gated 
(Figure 3.1D).   
 
3.3. CD8+ and CD4+ EMRA T cells increase significantly with age and are a 
highly heterogeneous population 
 
3.3.1. Utilisation of CD45RA/CD27 to identify CD8+ and CD4+ T cell subsets 
The CD8+ and CD4+ T cell lineages include four distinct subsets: naïve, CM, EM and 
EMRA. Phenotypically these subsets can be identified by flow cytometry using the 
cell surface markers CD45RA/CD27 (Henson et al., 2014; Koch et al., 2008); with  
naïve being defined as CD45RA+CD27+, CM CD45RA-CD27+, EM CD45RA-CD27- and 
EMRA CD45RA+CD27- (Figure 3.2A and B). The frequency of these four subsets were 
recorded for both CD8+ and CD4+ T cells in individuals aged 20 – 75 (Figure 3.2C). No 
difference was found in the percentage of naïve and EM T cells between the two 
lineages (Figure 3.2C); however, CD4+ T cells had significantly more CM T cells 









Figure 3.1: Utilisation of flow cytometry to identify CD8+ and CD4+ T cells 
A) SSC-A/FSC-A plot: Gate around lymphocytes. 
B) FSC-H/FSC-A plot: Gate around single cells. 
C) FSC-H/Zombie_NIR: Gate around live cells. 








Figure 3.2: Utilisation of CD45RA/CD27 to identify CD8+ and CD4+ T cell subsets 
A) Representative flow cytometry dot plot of CD8+ CD45RA/CD27 defined subsets.  
B) Representative flow cytometry dot plot of CD4+ CD45RA/CD27 defined subsets.  
C) Quantification of the CD45RA/CD27 defined CD8+ and CD4+ T cell subsets. 
Individuals were aged 20 – 75, with a median age of 45. Data expressed as mean 







The proportion of CD8+ naïve T cells decreased significantly with age (Figure 3.3A). 
This was accompanied by a significant increase in the CD8+ EMRA T cell population 
(Figure 3.3D). The proportions of CM and EM CD8+ T cells did not differ between the 




Figure 3.3: Age related changes to the frequency of CD8+ CD45RA/CD27 subsets 
Percentage of A) Naïve, B) CM, C) EM and D) EMRA CD8+ T cells defined as percentage 
of the total CD8+ T cells population stratified by age. The line of best fit was generated 




The proportion of CD4+ naïve T cells also decreased significantly with age (Figure 
3.4A). Both the CD4+ CM and EM subsets increased significantly with age (Figure 3.4B 
and C). Additionally, despite not being statistically significant, the CD4+ EMRA subset 




Figure 3.4: Age related changes to the frequency of CD4+ CD45RA/CD27 subsets 
Percentage of A) Naïve, B) CM, C) EM and D) EMRA CD4+ T cells defined as percentage 
of the total CD4+ T cells population stratified by age. The line of best fit was generated 




3.3.2. CD8+ and CD4+ EMRA T cells are a highly heterogeneous subset  
Previously data from our lab showed that the CD8+ EMRA T cell subset is highly 
heterogeneous (Figure 3.5), with a population that aligns to the naïve subset (N-like 
EMRA) and another that aligns more closely to the EM subset (EM-like EMRA) 
(Callender, Carroll, Beal, et al., 2018). To properly investigate the heterogeneity of 
the EMRA subset in both CD8+ and CD4+ T cells we used a phenotyping strategy that 
utilised the cell surface markers CD45RA, CCR7, CD27 and CD28 to define senescence 
(Koch et al., 2008).  
 
The leukocyte common antigen isoform CD45RA is expressed on naïve T cells but lost 
during memory development. However, terminally differentiated memory T cells re-
express CD45RA, therefore it can be used to define both naïve and EMRA T cells 
(Hamann et al., 1997, 1999). The chemokine receptor CCR7 facilitates T cell exit out 
of the periphery and into lymphoid tissues, making it vital for naïve T cells as it allows 
them to search lymphoid tissues for antigens. CM T cells also maintain high levels of 
CCR7 as they predominantly reside in lymph nodes (Koch et al., 2008). Conversely, 
EM and EMRA T cells lose CCR7 and are instead found predominantly in the blood 
and non-lymphoid tissues. The co-stimulatory molecules CD27 and CD28 are 
important for providing proliferative and survival cues to naïve T cells following 
antigen engagement. Both are lost during differentiation, therefore the loss of CD27 














Figure 3.5: Identification of naïve-like and EM-like EMRA subsets 
PCA analysis of anti-CD3 stimulated CD8+ CD45RA/CD27 defined subsets ran on U113 
Affymetrix human gene arrays (Data obtained from Dr. Siân Henson) (Callender, 
Carroll, Beal, et al., 2018).  
 
When CD8+ or CD4+ T cells were gated on CD45RA/CCR7, the CD45RA+CCR7- (EMRA) 
population was found to be highly heterogeneous, comprising of a N-like EMRA 
population expressing both CD27 and CD28 (CD27+CD28+) and a more differentiated 
EM-like EMRA population (CD27-CD28-) that lacked the expression of both of these 
markers (Figure 3.6A and C). Quantification of these two populations in individuals 
aged between 20 - 75 revealed that CD8+ EMRA T cells were comprised 
predominantly of the more differentiation EM-like EMRA T cells (Figure 3.6B), 
whereas CD4+ EMRA T cells were comprised mainly of the N-like EMRA population 
































Figure 3.6: EMRA T cells are a highly heterogeneous subset  
A) CD45RA/CCR7/CD27/CD28 phenotyping gating strategy on live, healthy CD8+ T 
cells. 
B) Percentage of CD8+ N-like (CD27+CD28+) and EM-like (CD27-CD28-) EMRA subsets. 
Individuals were aged 20 – 75, with a median age of 45. Data expressed as mean 
± SEM, n = 41. P value was determined using a paired T-test p**** = < 0.0001. 
C) CD45RA/CCR7/CD27/CD28 phenotyping gating strategy on live, healthy CD4+ T 
cells. 
D) Percentage of CD4+ N-like (CD27+CD28+) and EM-like (CD27-CD28-) EMRA subsets 
Individuals were aged 20 – 75, with a median age of 45. Data expressed as mean 





3.4. Investigating the senescent characteristics of CD8+ and CD4+ T cell subsets 
EMRA T cells display multiple characteristics of senescence, including high levels of 
DNA damage, loss of telomerase activity and low proliferative capacity (Henson et 
al., 2014; Di Mitri et al., 2011; Xu and Larbi, 2017). However, less is known about the 
senescent properties of the N-like and EM-like EMRA subsets. Therefore, various 
generic and T cell specific senescence markers were used to assess senescence in 
these subsets within both the CD8+ and CD4+ lineage.   
 
3.4.1. EMRA and EM-like EMRA T cells have elevated p-p53  
The transcriptional regulator p53 plays a vital role in the induction of senescence 
(Rufini et al., 2013). Therefore, intracellular staining of phosphorylated-p53 (p-p53) 
was carried out on PBMCs isolated from individuals aged 24 – 44 directly ex-vivo. As 
expected, CD8+ EMRA T cells were found to have the highest levels of p-p53 (Figure 
3.7A). Furthermore, the EM-like EMRA subset had significantly more p-p53 than the 
N-like EMRA subset (Figure 3.7B).  
 
Naïve CD4+ T cells were found to have the least amount of p-p53 (Figure 3.8A). The 
difference in p-p53 levels between the three memory populations followed the same 
trend as the CD8+ T cells, with the CD4+ EMRA T cells expressing the most p-p53. 
However, the differences were more pronounced than in the CD8+ T cell lineage 
(Figure 3.8A). The CD4+ EM-like EMRA subset also expressed high levels of p-p53; 
whereas, the p-p53 levels in the N-like EMRA subset were more comparable to the 







Figure 3.7: Levels of p-p53 in CD8+ T cell subsets 
A) MFI of p-p53 in CD8+ CD45RA/CD27 defined subsets. Individuals were aged 24 – 
44, with a median age of 28. Data expressed as mean ± SEM, n = 25. P values were 
determined using a repeated measures ANOVA with Tukey’s multiple 
comparisons test p* = 0.0134 and p** = 0.0022.  
B) MFI of p-p53 in CD8+ N-like (CD27+CD28+) and EM-like (CD27-CD28-) EMRA 
subsets. Individuals were aged 24 – 44, with a median age of 28. Data expressed 








Figure 3.8: Levels of p-p53 in CD4+ T cell subsets 
A) MFI of p-p53 in CD4+ CD45RA/CD27 defined subsets. Individuals were aged 24 – 
44, with a median age of 28. Data expressed as mean ± SEM, n = 25. P values were 
determined using a repeated measures ANOVA with Tukey’s multiple 
comparisons test p* = 0.0139, p** =0.0046 and p*** = < 0.0001.  
B) MFI of p-p53 in CD4+ N-like (CD27+CD28+) and EM-like (CD27-CD28-) EMRA 
subsets. Individuals were aged 24 – 44, with a median age of 28. Data expressed 





3.4.2. CD8+ and CD4+ EMRA T cells exhibit opposing proliferative capacity  
Loss of proliferative capacity is another key feature of senescent cells. Ki-67 is a 
nuclear protein that is present during all phases of the cell cycle. Its expression is 
believed to be a requirement for the progression of cell division; therefore, it is an 
excellent marker of proliferation (Gerdes et al., 1991). Intracellular staining of Ki-67 
was performed on PBMCs from individuals aged 24 – 64 directly ex vivo. Ki-67 levels 
were lowest in the CD8+ naïve T cells (Figure 3.9A) and the highest in the EM T cells. 
The CD8+ CM and EMRA subsets had similar levels of Ki-67, indicating a lower rate of 
proliferation in these memory subsets when compared with the EM subset. Further 
stratification of the CD8+ EMRA cells revealed that both N-like and EM-like EMRA 
subsets also had relatively low Ki-67 levels (Figure 3.9B).  
 
Intracellular Ki-67 levels were the lowest in the CD4+ naïve T cell subset and CD4+ CM 
and EM T cells had significantly higher levels of Ki-67 than the naïve subset (Figure 
3.10A). In contrast to CD8+ EMRA T cells, CD4+ EMRA T cells had the highest levels of 
Ki-67, however this was not found to be statistically significantly when compared to 
any of the other subsets, most likely due to the large variation in the data set (Figure 
3.10A) and also reflects the heterogeneity of the CD4+ EMRA subset. Interestingly, Ki-
67 levels found in the CD4+ EM-like EMRA subset were significantly higher than the 









Figure 3.9: Levels of Ki-67 in CD8+ T cell subsets 
A) Percentage of Ki-67 in CD8+ CD45RA/CD27 defined subsets. Individuals were aged 
24 – 64, with a median age of 27. Data expressed as mean ± SEM, n = 14. P values 
were determined using a repeated measures ANOVA with Tukey’s multiple 
comparisons test p* = 0.0364.  
B) Percentage of Ki-67 in CD8+ N-like (CD27+CD28+) and EM-like (CD27-CD28-) EMRA 
subsets. Individuals were aged 24 – 64, with a median age of 27. Data expressed 








Figure 3.10: Levels of Ki-67 in CD4+ T cell subsets 
A) Percentage of Ki-67 in CD4+ CD45RA/CD27 defined subsets. Individuals were aged 
24 – 64, with a median age of 27. Data expressed as mean ± SEM, n = 14. P values 
were determined using a repeated measures ANOVA with Tukey’s multiple 
comparisons test p** = 0.0074, p*** = 0.0003 and p**** = <0.0001. 
B) Percentage of Ki-67 in CD4+ N-like (CD27+CD28+) and EM-like (CD27-CD28-) EMRA 
subsets. Individuals were aged 24 – 64, with a median age of 27. Data expressed 





3.4.3. N-like EMRA T cells are not truly naïve 
The killer cell lectin-like receptor G1 (KLRG1) is upregulated on antigen-experienced 
T cells (Henson et al., 2009; Voehringer et al., 2002). Consequently, KLRG1 is a good 
indicator of antigen experience and a widely used marker of T cell senescence. 
Examination of CD8+ T cells from individuals aged 25 – 73 directly ex vivo revealed 
that KLRG1 levels were low on CD8+ naïve T cells but dramatically increased with 
memory development. However, no difference between the EM and EMRA memory 
populations was found (Figure 3.11A). Both CD8+ N-like and EM-like EMRA subsets 
expressed high levels of KLRG1; however, the EM-like EMRA KLRG1 levels were more 
comparable to that of the whole CD8+ EMRA T cell subset, suggesting that this is the 
more differentiated subset of the two (Figure 3.11B). KLRG1 levels in the CD8+ T cell 
compartment were significantly correlated with age (Figure 3.11C). Stratifying this 
correlation by subset revealed that this was due to an increase in KLRG1 in the naïve 
subset, as the three memory subsets showed no correlation with age (Figure 3.12). 
 
KLRG1 levels differed significantly between all CD4+ T cell subsets, with CD4+ naïve T 
cells expressing the least and CD4+ EMRA T cells expressing the most (Figure 3.13A). 
A significant difference was also observed between the N-like and EM-like EMRA 
subsets, with the EM-like EMRA cells expressing levels comparable to that of the 
whole CD4+ EMRA T cell subset (Figure 3.13B). KLRG1 levels in the CD4+ T cell 
compartment were significantly correlated with age (Figure 3.13C). Stratifying this 
correlation by subset revealed that KLRG1 levels increase with age in the naïve, EM 







Figure 3.11: Levels of KLRG1 in CD8+ T cell subsets 
A) Percentage of KLRG1 in CD8+ CD45RA/CD27 defined subsets with representative 
flow cytometry plots.  Individuals were aged 25 – 73, with a median age of 32. 
Data expressed as mean ± SEM, n = 30. P values were determined using a 
repeated measures ANOVA with Tukey’s multiple comparisons test, p**** = 
<0.0001. 
B) Percentage of KLRG1 in CD8+ N-like (CD27+CD28+) and EM-like (CD27-CD28-) 
EMRA subsets with representative flow cytometry plots. Individuals were aged 
25 – 73, with a median age of 32. Data expressed as mean ± SEM, n = 30. P value 
was determined using a paired T-test p*** = 0.0004. 
C) Age related changes to the percentage of KRLG1 in whole CD8+ T cells. The line of 








Figure 3.12: Age related changes to the percentage of KRLG1 in CD8+ T cell subsets 
Percentage of KLRG1 in A) Naïve, B) CM, C) EM and D) EMRA CD8+ T subsets. The line 












Figure 3.13: Levels of KLRG1 in CD4+ T cell subsets 
A) Percentage of KLRG1 in CD4+ CD45RA/CD27 defined subsets with representative 
flow cytometry plots. Individuals were aged 25 – 73, with a median age of 32. 
Data expressed as mean ± SEM, n = 30. P values were determined using a 
repeated measures ANOVA with Tukey’s multiple comparisons test, p*** = 
0.0007, p**** = <0.0001. 
B) Percentage of KLRG1 in CD4+ N-like (CD27+CD28+) and EM-like (CD27-CD28-) 
EMRA subsets with representative flow cytometry plots. Individuals were aged 
25 – 73, with a median age of 32. Data expressed as mean ± SEM, n = 30. P value 
was determined using a paired T-test p*** = 0.0001. 
C) Age related changes to the percentage of KRLG1 in whole CD4+ T cells. Line of 








Figure 3.14: Age related changes to the percentage of KRLG1 in CD4+ T cell subsets 
Percentage of KLRG1 in A) Naïve, B) CM, C) EM and D) EMRA CD4+ T subsets. Line of 






3.4.4. N-like EMRA T cells are distinct from replicative T cell senescence 
CD57 is another inhibitory receptor that is upregulated in response to persistent viral 
infections and therefore is widely associated with replicative senescence in T cells 
(Bandrés et al., 2000; Brenchley et al., 2003; Sze et al., 2001; Weekes et al., 1999). 
Examination of CD8+ T cells from individuals aged 25 – 74 directly ex vivo revealed 
that naïve and CM CD8+ T cells expressed very low levels of CD57 when compared 
with EM and EMRA T cells (Figure 3.15A). CD8+ EM-like EMRA T cells had significantly 
higher levels of CD57 when compared with the N-like subset (Figure 3.15B). 
Furthermore, CD57 levels in CD8+ T cells were positively correlated with age (Figure 
3.15C). When these age-related changes were stratified by subset the CD8+ naïve T 
cells were found to increase significantly with age, and although not statistically 
significant the CD8+ EMRA T cells also showed a positive trend towards increased 
CD57 with age (Figure 3.16). 
 
CD4+ EMRA T cells expressed significantly more CD57 than all other subsets (Figure 
3.17A). Furthermore, the CD4+ EM-like EMRA T cells expressed significantly more 
CD57 than the N-like subset (Figure 3.17B). Similar to what was observed in the CD8+ 
compartment, CD57 levels in whole CD4+ T cells were significantly correlated with 
age (Figure 3.17C). Surprisingly, stratifying these changes by subset revealed no 
significant correlation; however, CD4+ EM and EMRA T cells did show a positive trend 









Figure 3.15: Levels of CD57 in CD8+ T cell subsets 
A) Percentage of CD57 in CD8+ CD45RA/CD27 defined subsets with representative 
flow cytometry plots. Individuals were aged 25 – 74, with a median age of 31. 
Data expressed as mean ± SEM, n = 23. P values were determined using a 
repeated measures ANOVA with Tukey’s multiple comparisons test, p** = 0.0016, 
p**** = <0.0001. 
B) Percentage of CD57 in CD8+ N-like (CD27+CD28+) and EM-like (CD27-CD28-) EMRA 
subsets with representative flow cytometry plots. Individuals were aged 25 – 74, 
with a median age of 31. Data expressed as mean ± SEM, n = 23. P value was 
determined using a paired T-test p**** = <0.0001. 
C) Age related changes to the percentage of CD57 in whole CD8+ T cells. Line of best 







Figure 3.16: Age related changes to the percentage of CD57 in CD8+ T cell subsets 
Percentage of KLRG1 in A) Naïve, B) CM, C) EM and D) EMRA CD8+ T subsets. Line of 








Figure 3.17: Levels of CD57 in CD4+ T cell subsets 
A) Percentage of CD57 in CD4+ CD45RA/CD27 defined subsets with representative 
flow cytometry plots. Individuals were aged 25 – 74, with a median age of 31. 
Data expressed as mean ± SEM, n = 23. P values were determined using a 
repeated measures ANOVA with Tukey’s multiple comparisons test, p* = 0.0419, 
p** = 0.0041, p*** = <0.001. 
B) Percentage of CD57 in CD4+ N-like (CD27+CD28+) and EM-like (CD27-CD28-) EMRA 
subsets with representative flow cytometry plots. Individuals were aged 25 – 74, 
with a median age of 31. Data expressed as mean ± SEM, n = 23. P value was 
determined using a paired T-test p**** = <0.0001. 
C) Age related changes to the percentage of CD57 in whole CD4+ T cells. Line of best 







Figure 3.18: Age related changes to the percentage of CD57 in CD4+ T cell subsets 
Percentage of CD57 in A) Naïve, B) CM, C) EM and D) EMRA CD4+ T subsets. Line of 






It has been well document that age significantly impacts the CD8+ T cell compartment 
(Chou and Effros, 2013). Data presented in this chapter confirms this, as age was 
shown to result in both a significant decrease in naïve CD8+ T cells and an increase in 
CD8+ EMRA T cells. Although less dramatic, a similar observation was made in the 
CD4+ lineage. This shift from naïve T cell output to the accumulation of terminally 
differentiated EMRA T cells significantly narrows the diversity of the TCR repertoire. 
Consequently this contributes to many age-related problems such as the inability to 
respond to new and emerging diseases (Naylor et al., 2005). What has been less 
documented is the existence of multiple different senescent T cell populations. 
Heterogeneity within memory subsets has been documented previously (Henson et 
al., 2015; Pulko et al., 2016). For example, a CD8+ memory population with a naïve-
like phenotype (CCR7+CD45RA+CD28intCD95lo), long telomeres, and the ability to 
response to persistent viral infections, has previously been found to increase during 
ageing (Pulko et al., 2016). Data presented in this chapter focused on the diverse 
nature of a more terminally differentiated population of CCR7-CD45RA+ EMRA T cells. 
Both the CD8+ and CD4+ EMRA subsets were found to be highly heterogenic 
populations, which displayed characteristic of either naïve or effector memory cells, 
and were consequently termed N-like and EM-like subsets respectively (Callender, 
Carroll, Beal, et al., 2018). 
 
To become terminally differentiated it is assumed that T cells must first undergo 




results in multiple rounds of extensive proliferation, which eventually drives T cells 
into a replicatively driven senescence state (Chou and Effros, 2013). However, we 
know from fibroblasts that senescence can be triggered via many routes, such as 
oxidative or oncogenic stress (Richter and Zglinicki, 2007; Serrano et al., 1997; Zhu et 
al., 1998), and as such, the phenotypic properties of these cells are also likely to 
differ.  
 
In order to characterise the senescent properties of N-like and EM-like EMRA T cells 
p-p53, Ki-67, KLRG1 and CD57 were used. The phenotype of these subsets differed 
slightly depending on the T cell lineage; however, both CD8+ and CD4+ N-like EMRA T 
cells displayed less characteristics of senescence, as they exhibited lower p-p53, 
KLRG1 and CD57 than the EM-like subset. Despite having lower KLRG1 levels than the 
EM-EMRA, the amount of KLRG1 present on the N-like EMRAs were still high and 
exceeded the levels of KLRG1 present on the true naïve and CM subsets. Conversely, 
CD57 was virtually absent on both CD8+ and CD4+ N-like EMRAs. This discrepancy is 
interesting as both KLRG1 and CD57 are often used as markers of viral specific T cells 
and thought to indicate replicative senescence. However, as we have shown here, 
although KLRG1 and CD57 expression often correlates, the two receptors are not 
mutually exclusive. The simultaneous expression of KLRG1 and CD57 has been 
previously proposed to define truly terminally differentiated cells at a more 
advantaged stage of senescence (Ibegbu et al., 2006). Consequently, we conclude 




like EMRAs (KLRG1+CD57-) are a less differentiated subset generated via premature 
senescence.  
 
Both CD8+ and CD4+ naïve T cells began to express KLRG1 with age. This observation 
mirrors what has been previously shown in CD27+CD28+-defined CD8+ naïve T cells 
(Henson et al., 2009). Similar phenomena have been previously documented; for 
example, CD4+ naive T cells have been shown to proliferate and acquire a memory-
like phenotype under lymphopenic conditions (Min et al., 2003). Interestingly, when 
the naïve T cell pool is significantly depleted, certain memory T cells can acquire 
naïve-like qualities such as responding to de novo infections. This has been 
demonstrated in influenza-naïve aged mice, where the response to a new influenza 
infection was largely mediated by a population of cross-reactive virtual memory (VM) 
CD8+ T cells (Lanzer et al., 2018). VM T cells are distinct from true memory cells as 
they are generated in the absence of antigen (Cheung et al., 2009; Haluszczak et al., 
2009; White et al., 2016). Although these VM populations have been observed in 
mice, a similar population may also be generated in humans. Collectively, these 
studies suggest that age can trigger naïve T cells to become memory-like even in the 
absence of antigen activation. However, in the event of a de novo infection, some 
memory-like naïve cells may still be able to carry out their true naïve T cell functions.  
 
In this chapter, not only was there a reduction in the naïve T cell output in older 
individuals, but the naïve T cells that remained did not appear truly naïve. Over time 




pushed by additional cellular stresses into a prematurely arrested senescent 
phenotype such as the N-like EMRAs. Unlike their EM-like counterparts, these cells 
may be better able to respond to infections and carry out effector function. 
 
Despite both being heterogenic, the proportion of N-like and EM-like EMRA T cells 
differed between the CD4+ and CD8+ T cell compartments. CD8+ EMRAs showed a 
tendency to be more EM-like, whereas CD4+ EMRAs were more N-like. These 
differences along with the well established observation that CD4+ EMRA T cells are 
far rarer than their CD8+ counterparts highlight the need for further investigation into 
the inherent differences between CD4+ and CD8+ T cells when it comes to the 
induction of senescence. This line of inquiry is continued in the next chapter. 
 
In conclusion, this chapter revealed the existence of two distinct EMRA T cell 
populations – one that is generated by replicative senescence and the other by a 
telomere-independent mechanism. Overall, this chapter highlights the phenotypic 
plasticity of T cells and therefore challenges the traditional notion that T cell 








Chapter four: Lineage commitment determines the extent of T 
cell senescence 
4.1. Introduction  
One of the most striking observations in the field of senescent T cell research and in 
the data presented in the previous chapter is how the CD8+ and CD4+ compartments 
have different susceptibilities to senescence. CD8+ T cells are far more susceptible to 
both phenotypic and functional changes during ageing (Czesnikiewicz-Guzik et al., 
2008; Goronzy et al., 2007). Furthermore, the CD8+ EMRA T cell subset accumulates 
in higher proportions with age and are more prevalent following in vitro culture than 
CD4+ EMRA T cells (Czesnikiewicz-Guzik et al., 2008). The cause of this difference has 
been previously attributed to the differing homeostatic mechanisms among the two 
lineages and to the increased gene expression instability of regulatory cell surface 
molecules in the CD8+ EMRA subset (Czesnikiewicz-Guzik et al., 2008). However, a 




The aim of this chapter was to assess the differences observed between CD8+ and 
CD4+ T cells with regards to their susceptibilities to senescence. In particular, the aim 
was to examine whether cell metabolism and mitochondrial health could play a 





4.2. CD4+ EMRA T cells develop at a slower rate than CD8+ EMRA T cells 
Both CD8+ and CD4+ EMRA T cells exhibit characteristics of senescence (Appay et al., 
2008; Henson et al., 2014; Di Mitri et al., 2011). However, the percentage of CD4+ 
EMRA T cells is small (Figure 4.1A), particularly when compared to the percentage of 
CD8+ EMRA T cells that accumulate with age (figure 4.1B). Therefore, these data 





Figure 4.1: The accumulation of CD27/CD45RA-defined EMRA T cells with age 
Percentage of EMRA T cells defined as percentage of the total (A) CD4+ or (B) CD8+ T 
cells population stratified by age. The line of best fit was generated using linear 
regression, n = 41. The data presented here was originally shown in Chapter 3 








4.3. CD4+ EMRA T cells retain a high mitochondrial mass due to an increase in 
mitochondrial biogenesis 
CD8+ EMRA T cells are known to have defective mitochondria and impaired OXPHOS, 
which contributes to the senescent characteristics of this cell type (Henson et al., 
2014). However, less is known about the health of CD4+ EMRA mitochondria and 
subsequent respiration. To evaluate whether CD4+ EMRA T cells also have 
mitochondria dysfunction, mitochondrial mass was assessed using Mitotracker green 
FM. Overall all of the CD4+ CD27/CD45RA defined subsets had a higher mitochondrial 
mass when compared to their CD8+ counterparts (Figure 4.2A). This difference was 
most striking between the EMRA subsets (Figure 4.2A). The data was obtained using 
middle aged donors with a median age of 41; however, when comparing this to a 
larger data set in our lab (Data not shown), this phenomenon was found to be 
independent of chronological age. 
 
To further investigate this, intracellular staining of PGC1α, the key regulator of 
mitochondrial biogenesis, was carried out. PGC1α levels were the lowest in CD8+ 
EMRA T cells, but the highest in CD4+ EMRA T cells (Figure 4.2B). Levels amongst the 
two naïve and CM subsets were unchanged; however, both CD4+ EM and EMRA T 
cells had significantly more levels of PGC1α than their CD8+ counterparts (Figure 
4.2B). Collectively these data showed that CD4+ EM and in particular EMRA T cells 









Figure 4.2: Assessment of mitochondrial mass in CD8+ and CD4+ T cell subsets 
A) Quantification of Mitotracker green MFI in CD8+ and CD4+ CD45RA/CD27 defined 
subsets with representative flow cytometry histograms from middle aged donors. 
Data expressed as mean ± SEM, n = 9. P values were determined using a two-way 
repeated measure ANOVA with Bonferroni multiple comparisons test, p* = 
0.0166, p*** = < 0.001. 
B) Quantification of PGC1α MFI in CD8+ and CD4+ CD45RA/CD27 defined subsets 
with representative flow cytometry histograms from middle aged donors. Data 
expressed as mean ± SEM, n = 9. P values were determined using a two-way 
repeated measure ANOVA with Bonferroni multiple comparisons test, p*** = 




4.4. CD4+ EMRA T cells have hyperpolarised mitochondria  
To determine whether the increased mitochondrial mass in the CD4+ EMRA subset 
was of functional importance TMRE, which measures MMP was used. CD8+ T cell 
subsets had a high proportion of hypopolarised mitochondria (Figure 4.3A) whereas, 
CD4+ Naïve, CM and EM subsets had a high proportion of healthy, intermediate MMP 
(Figure 4.3B). In contrast to the other CD4+ subsets, CD4+ EMRAs had a high 
proportion of hyperpolarised mitochondria (Figure 4.3B). This was also in complete 
contrast to the CD8+ EMRAs, which predominantly displayed a hypopolarised 
phenotype (Figure 4.3A). The MMP provides the charge gradient required for Ca2+ 
sequestration and the regulation of ROS production. Cell stress causes MMP 
dysregulation, with hyperpolaristion resulting in the production of excess ROS. 
However, a state of hypopolarisation is also harmful, as low amounts of ROS cause 
reductive stress, which can be as detrimental to homeostasis as oxidative stress 
(Zorova et al., 2018). 
 
As hyperpolarised mitochondria are a source of ROS (Mills et al., 2016; Siska et al., 
2017) we assessed mitochondrial ROS (mtROS) using MitoSox. Although ROS levels 
were the highest in CD4+ EMRAs (Figure 4.4A) this increase was neutralised owing to 
the higher mitochondrial mass, meaning that CD8+ EMRA T cells produced more ROS 
per mitochondria (Figure 4.4B). This data could suggest that the increased 
mitochondrial mass observed in CD4+ EMRA T cells is a protective mechanism to 
ensure that CD4+ EMRA T cells are able to adequately buffer the excess ROS (Zorov 







Figure 4.3: Assessment of MMP (ΔΨm) in CD8+ and CD4+ T cell subsets 
Representative flow cytometry histograms and cumulative graphs of TMRE staining 
in (A) CD8+ and (B) CD4+ CD45RA/CD27 defined subsets from middle aged donors. 













Figure 4.4: mtROS levels in CD8+ and CD4+ T cell subsets 
A) Representative histograms and quantification of MitoSOX MFI in CD8+ and CD4+ 
CD45RA/CD27 defined subsets from middle aged donors. Data expressed as 
mean ± SEM, n = 8. P values were determined using a two-way repeated measure 
ANOVA with Bonferroni multiple comparisons test, p* = < 0.05, and p** = 0.0028. 
B) mtROS production expressed as a ratio of mitochondrial mass in CD8+ and CD4+ 
CD45RA/CD27 defined subsets from middle aged donors. Data expressed as 
mean ± SEM, n = 8. P values were determined using a two-way repeated measure 




4.5. CD4+ EMRA T cells retain their oxidative capacity  
To probe this further we next sought to investigate whether the increased 
mitochondrial mass and hyperpolarised MMP in CD4+ EMRA T cells led to metabolic 
reprogramming. To do this we used a mitochondrial stress test to measure the 
bioenergetics profiles of TCR stimulated CD45RA/CD27 defined T cell subsets (Figure 
4.4). The mitochondrial stress test includes the addition of four pharmacological 
drugs that manipulate OXPHOS. The ATP synthase inhibitor oligomycin is the first to 
be injected and enables the amount of oxygen used for ATP production to be 
calculated. Secondly, FCCP is added to uncouple the ETC from ATP synthesis. This 
collapses the MMP and allows the cells spare respiratory capacity (SRC) to be 
calculated. Lastly, rotenone and antimycin A, which are complex 1 and 3 inhibitors 
are added to allow for the non-mitochondrial oxygen consumption to be calculated.  
 
Naïve CD4+ T cells had significantly lower basal oxygen consumption compared to the 
memory T cells, however no differences were found amongst the three CD4+ memory 
subsets (Figure 4.5A and B). Furthermore, the SRC was also significantly lower in the 
naïve CD4+ T cells but unchanged in the three memory subsets (Figure 4.5A and C). 
The oxidative capacity of CD8+ T cell subsets has been previously published (Henson 
et al., 2014); however for comparison the biogenetic profile for CD8+ EMRAs have 
been included (Figure 4.5A). Similar results were found using unstimulated cells (Data 
not shown). However, as the OCR was much lower and the differences were less 








Figure 4.5: The bioenergetics profiles of CD45RA/CD27 defined T cell subsets 
A) OCR of the CD4+ T cell subsets and CD8+ EMRA T cells from middle aged donors 
were measured after 15-minute stimulation with 0.5 μg/ml anti-CD3 and 5 ng/ml IL-
2, cells were subjected to a mitochondrial stress test using indicated mitochondrial 
inhibitors. Data are representative of 4 independent experiments.  
B) Basal OCR and C) the SRC after 15-minute stimulation with 0.5 μg/ml anti-CD3 and 





4.6. CD4+ and CD8+ EMRAs have different nutrient uptake  
T cells utilise a variety of energy sources including glucose and lipids; however, their 
metabolic preferences are governed not only by their differentiation status but also 
by mitochondria fitness. Furthermore, a lack of regulatory control over nutrient 
usage is a recurrent theme accompanying senescence and ageing. We therefore 
sought to determine whether there were differences in glucose and FA uptake in the 
CD8+ and CD4+ T cell subsets. CD8+ EMRAs were found to take up far less of the 
fluorescent glucose analogue; 2-NBDG, from their extracellular environment than 
their CD4+ EMRA counterparts (Figure 4.6A). Glucose is internalised via GLUT1, the 
major glucose transporter in T cells, therefore internalisation is key for glucose 
uptake in T cells. The GLUT1 external/internal ratio can be used to assess 
internalisation. Here, CD8+ EMRA T cells had the highest external/internal ratio and 
therefore had the least internalisation of GLUT1 and glucose (Figure 4.6B). This defect 
was not found in the CD4+ EMRA T cells (Figure 4.6B).  
 
The uptake of fluorescently labelled palmitate; BODIPY C16, a long chain FA was also 
quantified. BODIPY C16 uptake was significantly increased in CD4+ EMRA T cells 
(Figure 4.7A). Furthermore, CD4+ EMRA T cells had higher levels of the FA translocase 
CD36 (Figure 4.7B) and the FA transporters FATP2 and -3 (Figure 4.7C and D). Taken 
together these results suggest the CD4+ EMRA T cells can utilise a variety of different 
nutrients. This could make them more adaptable, allowing them to maintain their 
health and fitness and potentially limit the impact of senescence. However, more 






Figure 4.6: Glucose uptake in CD8+ and CD4+ T cell subsets  
A) Glucose uptake was assessed using the fluorescent glucose analog 2-NBDG in 
CD4+ and CD8+ CD45RA/CD27 defined subsets from middle aged donors by flow 
cytometry following a 15-minute incubation. Data expressed as mean ± SEM, n = 
8. P values were determined using a two-way repeated measure ANOVA with 
Bonferroni multiple comparisons test, p** = 0.0041, p*** = 0.0003 and p**** = 
<0.0001. 
B) GLUT1 internalisation was determined by calculating the external/internal GLUT1 
ratio of GLUT1 obtained from flow cytometry analysis of surface and intracellular 
staining of GLUT1. All individuals were middle aged donors. Data expressed as 
mean ± SEM, n = 6. P values were determined using a two-way repeated measure 






Figure 4.7: Lipid uptake in CD8+ and CD4+ T cell subsets  
A) Lipid uptake was assessed using the fluorescent palmitate analog BODIPY C16 in 
CD4+ and CD8+ CD45RA/CD27 defined subsets by flow cytometry following a 10-
minute incubation. Data expressed as mean ± SEM, n = 8. P values were 
determined using a two-way repeated measure ANOVA with Bonferroni multiple 
comparisons test, p**** = <0.0001. 
B) Percentage of CD36+ cells, C) MFI of FATP2 and D) FATP3 in CD8+ and CD4+ EMRA 
T cells. Data expressed as mean ± SEM, n = 10. P values were determined using a 





4.7. GATA3 is highly expressed in CD4+ T cells  
The metabolic differences observed between CD8+ and CD4+ EMRA led us to 
hypothesise that there was an inherent difference in the CD4+ T cell lineage, which 
was offering protection against the induction of senescence through increasing 
mitochondrial mass and fitness. Consequently, we investigated the transcription 
factor GATA3, which is essential for CD4+ lineage commitment during early T cell 
development in the thymus (Hernández-Hoyos et al., 2003). GATA3 is also required 
for Th2 differentiation and has therefore been regarded as a marker for Th2 cells 
(Zheng and Flavell, 1997). Surprisingly, we found that CD4+ EMRA T cells had the 
highest levels of GATA3 when compared with the other three subsets (Figure 4.8), 
despite being more Th1 like – determined by increased IFN-ƴ and decreased IL-4, IL-
5 and IL-13 cytokine production (Appay et al., 2008; Das et al., 2017; Sakata-Kaneko 
et al., 2000). In the CD8+ lineage, GATA3 remained unchanged amongst the four 
subsets (Figure 4.8). 
 
4.8. DNA damage recruits a GATA3-PGC1α complex  
A possible connection between GATA3 and mitochondria has been previously 
reported. A yeast two hybrid screen showed that GATA3 is able to interact with the 
DNA damage proteins; ATM and ATR, as well as PGC1α (Kim et al., 2007). DNA 
damage can occur for a number of reasons. For instance, cells which undergo rapid 
proliferation tend to accumulate DNA damage, as well as many end-stage cells that 
have undergone replicative senescence in response to telomere dysfunction (Harley 







Figure 4.8: GATA3 in CD8+ and CD4+ T cell subsets  
Representative histograms and cumulative GATA3 data in CD4+ and CD8+ 
CD45RA/CD27 defined subsets from middle aged donors. Data expressed as mean ± 
SEM, n = 8. P values were determined using a two-way repeated measure ANOVA 






Data from the previous chapter showed that CD4+ EMRA T cells have elevated levels 
of the downstream DNA damage response protein p53 (Figure 3.10 and 3.11). 
Immunoprecipitation (IP) assays showed that GATA3, PGC1α and the DNA damage 
protein; ATR, existed in the same complex in CD4+ EMRA T cells (Figure 4.9A). GATA3 
was bound to CHEK1, the downstream ATR kinase in all four CD4+ T cells subsets; 
however, CD4+ EMRA T cells had the highest levels of GATA3 bound to the ATR in all 
three repeats (Figure 4.9B). Little to no PGC1α was bound to the ATR in naïve and CM 
T cells, a small amount was bound in the EM subset; however, the EMRA T cell had a 
marked increase in the amount of PGC1α bound to the ATR (Figure 4.9C). To validate 
this additional IP experiments are being conducted in the lab using GATA3 and PGC1α 
pulldowns.  
 
To mimic DNA damage, we incubated CD4+ T cells with hydroxyurea; a DNA 
replication inhibitor known to induce DNA double strand breaks (Bianchi et al., 1986; 
Timson, 1975). Overnight incubation with hydroxyurea resulted in a significant 
increase in the amount of p-p53 (Figure 4.10A). Furthermore, IP assays showed that 
following treatment with hydroxyurea increased amounts of GATA3 and PGC1α were 
bound to the ATR (Figure 4.10B). In addition, flow cytometry analysis revealed a 
significant increase in PGC1α (Figure 4.11A) and an increased mitochondrial content, 
determined by elevated Mitotracker green staining (Figure 4.11B). Future 
experiments will include testing a range of different hydroxyurea concentrations to 








Figure 4.9: CHEK1 immunoprecipitation in CD4+ T cell subsets  
(A) Representative image of western blot after CHEK1 immunoprecipitation in the 
CD27/CD45RA defined CD4+ T cell subsets and cumulative graphs to quantify the 
amount of (B) GATA3 and (C) PGC1α bound to the CHEK1 antibody. Data show as 












Figure 4.10: CHEK1 immunoprecipitation following hydroxyurea induced DNA 
damage in CD4+ T cells  
A) Graph to show the p-p53:p53 ratio following induction of DNA damage by 
hydroxyurea in whole CD4+ T cells. Data expressed as mean ± SEM, n = 5.  
B) Representative image of western blot after CHEK1 immunoprecipitation in CD4+ 
T cells following exposure to hydroxyurea.  
C) Quantification of GATA3 and D) PGC1α bound to the CHEK1 antibody following 
IP. Data expressed as mean ± SEM, n = 3. P values were determined using a paired 









Figure 4.11: PGC1α and GATA3 following hydroxyurea induced DNA damage in CD4+ 
T cells  
A) Representative histograms and cumulative data of intracellular PGC1α levels 
following the induction of DNA damage by hydroxyurea in whole CD4+ T cells. 
Data expressed as mean ± SEM, n = 6. P value was determined using a paired T-
test, p* = <0.05. 
B) Representative histograms and cumulative data of intracellular GATA3 levels 
following the induction of DNA damage by hydroxyurea in whole CD4+ T cells. 






4.9. GATA3 directly regulates CD4+ T cell metabolism and mitochondrial 
biogenesis  
To verify that GATA3 can directly regulate mitochondria biogenesis and fitness, we 
used small interfering RNA (siRNA) to reduce GATA3 expression in purified human 
CD4+ T cells following activation (Figure 4.12). Transfection with GATA3 siRNA led to 
a significant decrease in both the levels of PGC1α (Figure 4.13A) and Mitotracker 
Green staining (Figure 4.13B), signifying a marked reduction in mitochondrial mass. 
Confocal microscopy examination of Tom20 (Figure 4.14A), a major outer 
mitochondrial membrane receptor and therefore mitochondrial marker, showed a 
significant reduction in both mitochondrial mass (Figure 4.14B) and volume (Figure 
4.14C) in Jurkat cells following transfection with GATA3 siRNA.  
 
TMRE staining revealed a dramatic shift from hyperpolarised to hypopolarised MMP 
in the GATA3 siRNA transfected CD4+ T cells, but not the scrambled siRNA transfected 
CD4+ T cells (Figure 4.15A). Moreover, transfection with GATA3 siRNA dramatically 
inhibited the ability of CD4+ T cells to perform OXPHOS when compared with CD4+ T 
cells transfected with negative control scrambled siRNA (Figure 4.16B). Basal OCR 
and SRC were significantly decreased in the GATA3 siRNA transfected CD4+ T cells 
(Figure 4.16C and D). Taken together, these data provide evidence that GATA3 is 










Figure 4.12: GATA3 siRNA knockdown efficacy in CD4+ T cells  
A) Quantification of GATA3 siRNA-AF647+ cells in CD4+ T cells transfected with 
either scrambled control siRNA or GATA3 siRNA with representative flow 
cytometry plots. Data expressed as mean ± SEM, n = 6. 
B) Percentage of live cells determined by Zombie NIR staining following GATA3 
siRNA transfection. Data expressed as mean ± SEM, n = 6 
C) GATA3 levels following siRNA knockdown in CD4+ T cells with representative 









Figure 4.13: PGC1α and GATA3 following GATA3 siRNA knockdown in CD4+ T cells  
A) Representative histograms and cumulative graph of PGC1α in CD4+ T cells 
following siRNA knockdown representative flow cytometry plots. Data expressed 
as mean ± SEM, n = 5. P value was determined using a paired T-test, p** = 0.0084. 
B) Representative histograms and cumulative graph of Mitotracker in CD4+ T cells 
following siRNA knockdown representative flow cytometry plots. Data expressed 









Figure 4.14: Assessment of mitochondria following GATA3 siRNA knockdown by 
confocal microscopy   
A) Representative images of Tom20 staining in Jurkat cells transfected with either 
scrambled negative control siRNA or GATA3 siRNA.  
B) Mitochondrial mass determined using Tom20 signal intensity. Data expressed as 
mean ± SEM, data from 3 individual experiments. 
C) Mitochondrial volume was determined through 3D rendering of Tom20 staining 











Figure 4.15: The MMP of CD4+ T cells after GATA3 siRNA knockdown 
Representative flow cytometry histograms and cumulative graphs of TMRE staining 
in CD4+ T cells transfected with either scrambled negative control siRNA or GATA3 
siRNA CD45RA/CD27 defined subsets. Data expressed as mean ± SEM, n = 6. P values 
were determined using a two-way repeated measure ANOVA with Bonferroni 









Figure 4.16: Bioenergetics profiles of CD4+ T cells following GATA3 siRNA knockdown  
A) OCR of CD4+ T cells following siRNA knockdown with either scrambled control 
siRNA or GATA3 siRNA was measured after 15-minute stimulation with 0.5 μg/ml 
anti-CD3 and 5 ng/ml IL-2, cells were subjected to a mitochondrial stress test using 
indicated mitochondrial inhibitors. Data are representative of 3 independent 
experiments.  
B) Basal OCR and C) the SRC after 15-minute stimulation with 0.5 μg/ml anti-CD3 and 




4.10. Discussion  
Senescent or EMRA T cells are a highly dynamic and heterogeneous subset of cells 
that accumulate with age (Callender, Carroll, Beal, et al., 2018), and are found in both 
the CD8+ and CD4+ T cell compartments. In addition to data presented in this thesis, 
others have shown that the CD8+ EMRA subset accumulates more rapidly than their 
CD4+ counterparts with age (Czesnikiewicz-Guzik et al., 2008; Koch et al., 2008). It 
has been suggested that the CD4+ EMRA subset is more resistant to the effects of age 
owing to better homeostatic control compared to that of CD8+ T cells. However, data 
in this chapter provides evidence that CD4+ T cells are protected against the effects 
of senescence due to the induction of a GATA3-PGC1α complex in the presence of 
DNA damage.  
 
Mitochondrial dysfunction is a central event in many pathologies and contributes to 
age-related processes. Mitochondria have been shown to participate in every aspect 
of ageing, such as a decline in stem cell function, cellular senescence and the 
development of the low grade inflammatory state (Sun et al., 2016). Alterations that 
occur to mitochondria with age are numerous, including reductions in mitochondrial 
mass (Corsetti et al., 2008), defects in mitochondrial biogenesis (Reznick et al., 2007), 
and impaired mitochondrial function in terms of ATP production and respiratory 
chain capacity (Preston et al., 2008).  Indeed, here we show that the CD8+ EMRA 
subset displayed a reduced mitochondrial mass, impaired mitochondrial biogenesis, 




CD4+ EMRA subset, demonstrating that CD8+ EMRA T cells had a greater degree of 
mitochondrial impairment compared to CD4+ EMRA T cells.  
 
Increased ROS levels have been demonstrated to be critical for the induction and 
maintenance of cell senescence (Davalli et al., 2016). The MMP is the central 
bioenergetic parameter controlling the generation of ROS (Nicholls, 2004). The 
CD8+ EMRA subset displayed a hypopolarised phenotype; whereas, the CD4+ EMRAs 
were in a hyperpolarised state. As expected from cells that display a high MMP, 
CD4+ EMRAs produced more ROS than their CD8+ counterparts. However, the higher 
mitochondrial content observed in CD4+ EMRA T cells means these cells have more 
buffering capacity to quench the effects of ROS. Consequently, CD4+ EMRA T cells are 
better at controlling the damaging effects of ROS and are therefore better able to 
control the rate of senescence (Zorov et al., 2014). 
 
Mitochondria also play a key role in cellular metabolism, they house the ETC and the 
tricarboxylic acid cycle (TCA) cycle, as well as playing crucial roles in the synthesis and 
breakdown of lipids (Pence and Yarbro, 2018). Metabolic regulation plays an 
important role during cellular senescence, with dysregulated metabolism now 
identified as a feature of many different cell types, including T cells (Callender, 
Carroll, Bober, et al., 2018). There is increasing evidence that cell cultures become 
glycolytic as they age, depending on the senescence induction method used 
(Callender, Carroll, Bober, et al., 2018; James et al., 2015). CD8+ EMRA T cells have 




al., 2014). However, here CD4+ EMRAs were able to maintain their metabolic 
flexibility as they retain better oxidative capacity than their CD8+ counterparts. 
Furthermore, they also retain better glucose and lipid uptake together with increased 
expression of transporters.  
 
Mechanistically, this increase in mitochondrial mass was found to be due to elevated 
levels of GATA3 caused by DNA damage. This led to the recruitment of a GATA3- 
PGC1 complex that induced mitochondrial biogenesis in CD4+ T cells. Furthermore, 
functional analysis of CD4+ T cells showed that GATA3 was crucial for T cell 
metabolism, as GATA3 knockdown impaired mitochondrial function and abolished 
the cells oxidative capacity. 
 
Importantly, the observation that the GATA3-PGC1α complex is induced by DNA 
damage suggests that this mechanism may not be restricted to the lymphocyte 
lineage. Especially as GATA3 is expressed in a wide variety of tissues outside the 
haematopoietic system and has been implicated in the tumourigenesis of many 
cancers such as luminal breast cancer (Mehra et al., 2005), neuroblastoma (Peng et 
al., 2015), endometrial carcinomas (Engelsen et al., 2008), as well as in human T cell 
acute lymphoblastic leukaemia (Minegishi et al., 1997) and CD4+CD8+ double positive 
T cell lymphoma (van Hamburg et al., 2008). GATA3-positive breast cancers have 
been shown to be highly differentiated, with resulting tumours two-fold larger in size 
than control tumours (Kouros-Mehr et al., 2008). In contrast, GATA3-negative breast 




et al., 2008). However, despite being associated with low metastatic potential and 
therefore a more favourable prognosis, GATA3-positive tumours are also associated 
with resistance to chemotherapy (Tominaga et al., 2012). In light of the data 
presented in this chapter, we hypothesise that the accumulation of DNA damage 
generated during chemotherapy would recruit the GATA3-PGC1α complex, allowing 
GATA3-positive tumours to maintain mitochondrial fitness and evade chemotherapy 
induced apoptosis. However, additional examination of GATA3 and its contribution 
to mitochondrial biogenesis in cancer is needed to confirm this.  
 
More broadly, these data implicate that transcription factors are likely to serve 
additional functions after their initial roles in differentiation. This is already the case 
for the Th1 differentiation marker; T-bet, which is also known to be crucial for long-
term memory in CD8+ T cells (Intlekofer et al., 2005; Juedes et al., 2003) and 
maturation of NK cells (Townsend et al., 2004). More recently; STAT5, which has 
traditionally been associated with cytokine signalling and JAK kinases (Beyer et al., 
2011), has now also been identified as a central regulator of naïve CD4+ T cell 
metabolism (Jones et al., 2019). Furthermore, although the GATA proteins have 
restricted expression patterns to some extent their functions can be interchangeable. 
For example, GATA1, - 2, and-4 can all activate the expression of GATA3 target genes 
IL-4 and IL-5 and repress IFN-ƴ in T cells (Ranganath and Murphy, 2002). Interestingly, 
GATA4 has previously been shown to become activated in the presence of the ATM 




(Kang et al., 2015). These functional overlaps suggest that other GATA proteins may 
also be capable of influencing cell metabolism.  
 
In summary, this chapter identified a previously unknown role for GATA3 in inducing 
mitochondrial biogenesis in response to DNA damage, revealing it as a key mediator 
cell metabolism and demonstrating that mitochondrial mass controls the senescence 






Chapter Five: T2D as a model to investigate different 
mechanisms for senescent T cell generation 
 
5.1. Introduction 
Senescent T cells have been implicated in a number of different chronic, 
inflammatory diseases, such as cancer (Zelle-Rieser et al., 2016), obesity (Shirakawa 
et al., 2016) and RA (Weyand et al., 2014). T2D, which is characterised by metabolic 
imbalances and chronic inflammation, becomes more prevalent with age (Duncan et 
al., 2003). Consequently, T2D was chosen as a model to investigate the relationship 
between inflammation, metabolism and T cell senescence. A full assessment of T cell 
senescence in T2D has not been conducted. However, CD4+CD28- T cells, which are a 
mixture of both EM and EMRA T cells, have been found to accumulate in T2D 
(Giubilato et al., 2011). More recently, CD8+CD28-CD57+ T cells have also been shown 
to increase the risk of hyperglycaemia in humans, highlighting a potential role for this 
subset in the pathogenesis of T2D (Lee et al., 2019). As T2D is characterised by both 
disrupted glucose homeostasis and chronic inflammation we hypothesised that this 









In chapter three the existence of multiple EMRA populations were revealed. To 
investigate potential mechanisms responsible for premature senescence in T cells, 
the aim of this chapter was to compare senescent T cells from people living with T2D 
and healthy individuals. Due to their abundance and increased susceptibility to 
senescence we decided to focus solely on the CD8+ T cell lineage.  
 
5.2. Characteristics of T2D and healthy volunteers 
People living with T2D were recruited from the DARE database (Table 5.1). T2D 
individuals had a median age of 64 years and had been living with T2D for a significant 
amount of time, with the mean length of time since diagnosis being 15 years. All 
people living with T2D were on medication, with the majority taking 3 – 6 different 
types of medication to control their condition (Table 5.1 and 5.2). Participation in the 
study was entirely voluntary and all individuals were required to travel in order for 
their blood to be collected meaning all T2D donors were fit enough to make this 
journey.  
 
Healthy age-matched control donors were recruited internally and had a median age 
of 62. Healthy volunteers were individuals who had not had an infection or 
immunisation within the last month, no known immunodeficiency, and had not 





Donor characteristics T2D donors Control donors 
Total number of donors 52 23 
Age ranges 50 - 77 years 49 – 73 years  
Median age 64 62 
Gender (Male / Female) 65% / 35% 48% / 52%  
Mean length of time since diagnosis 15 years N/A 
Medication(s):       1 – 2 
    3 – 6 






Table 5.1: Donor characteristics 
 
Category List of medications (% of patients taking medication) 
Diabetes  Metformin (74%), Glizcazide (20%), Canagliflozin (6%), Humalog (6%), 
Dulaglutide (2%), Levemir (4%), Glargine (2%), Victoza (2%), Gliptin (2%). 
Statins Atrovastatin (44%), Simvastatin (8%), Pravastatin (6%). 
Other Aspirin (22%), Rampril (20%), Candesartan (8%), Amlodipine (6%), Bendro 
(6%), Pregabalin (4%), Citalopram (4%), Tramadol (4%), Doxazosin (4%), 
Levothyroxine (4%), Solifenacin (4%), Bisoprolol (2%), Morphine (2%), 
Quinninesulphate (2%), Colecalciferol (2%), Taddalafil (2%), Travopost 
(2%), Fenofibrate (2%), Spironolactone (2%), Bendroflumethiazide (2%), 
Beclomethasone dipropionate (2%), Salamol (2%), Trimethoprim (2%), 
Paroxetine (2%), Isosorbide mononitrate (2%), Omeprazole (2%), 
Edoxaban (2%), Tamsulosin (2%). 
 




5.3. People living with T2D have a prematurely aged CD8+ T cell phenotype 
The cell surface markers CD45RA and CD27 were used to quantify the frequency of 
CD8+ T cell subsets in people living with T2D compared with healthy age-matched 
control donors (Figure 5.1A, B and C). T2D donors had a significant reduction in the 
number of CD8+ naïve T cells, which was mirrored by a significant increase in the 
number of CD8+ EMRA T cells (Figure 5.1C), demonstrating that people living with 
T2D have a prematurely aged T cell phenotype. To assess the potential impact of 
medications we compared the percentage of CD8+ EMRA T cells with the total 
number of drugs, however no relationship was found (Figure 5.2). 
 
Examination of a range of cell surface markers (CD27, CD28, CD45RA, CCR7, and 
KLRG1) through an unbiased t-SNE analysis further supported this finding (Figure 
5.3A). t-SNE is a machine learning algorithm that clusters data based on how similar 
the data points are and when combined with the heatmap expression data, the 














Figure 5.1: Utilisation of CD45RA/CD27 to assess CD8+ subsets in people living with 
T2D and healthy control donors  
A) Representative flow cytometry dot plot of CD8+ CD45RA/CD27 defined subsets 
from a healthy age-matched control donor.  
B) Representative flow cytometry dot plot of CD8+ CD45RA/CD27 defined subsets 
from a T2D donor.  
C) Quantification of the CD45RA/CD27 defined CD8+ T cell subsets in T2D and 
healthy age-matched control donors. Data expressed as mean ± SEM, n = 22 
control, 22 T2D. P values were determined using a two-way ANOVA with 










Figure 5.2: The relationship between T2D CD8+ EMRA T cells and medication 
Percentage of CD8+ EMRA T cells defined as percentage of the total CD8+ T cell 
population against the total number of medications, n = 22. Line of best fit generated 





The t-SNE analysis revealed a dramatic loss in the number of true naïve CD8+ T cells 
(CD27+CD28+CCR7+CD45RA+KLRG1-) in people living with T2D (Figure 5.3A and B). 
Interestingly, the t-SNE also revealed the existence of multiple EMRA populations, 
further supporting the notion that EMRA T cells are highly heterogeneous (Figure 
5.3A and B). EMRA 1, 2 and 3 were all CD45RA+CD27- but expressed varying degrees 
of CD28 and CCR7. As expected, all 3 of these EMRA subsets also expressed high 
levels of KLRG1 (Figure 5.4A and B). Surprisingly, there was a dramatic loss in the 
number of EMRA 3 cells in the T2D donors (Figure 5.3A and B). However, an 
additional CD45RA+CD27- EMRA subset, which lacked the expression of KLRG1 was 
identified (Figure 5.4A and B). This subset was increased greatly in T2D donors and 
following additional experiments, which will appear in the latter half this chapter, 
this subset was later termed inflammatory-derived EMRA (i-EMRA). In addition to 
changes to the EMRA populations, the CM 1 cluster was also dramatically increased 
in T2D donors (Figure 5.3A and B).  
 
Collectively, the t-SNE analysis further supported the notion that EMRA T cells are 













Figure 5.3: t-SNE cluster analysis of CD8+ T cells in T2D and control donors  
A) Clusterplot analysis of CD8+ T cells in control and T2D donors using CD27, CD28, 
CD45RA, CCR7 and KLRG1, n = 6. 
B) Rate change plot showing the change in the percentage of cells in each group 







Figure 5.4: Marker expression data from t-SNE analysis  
A) Heatmap to show protein levels of cell surface markers CD27, CD28, CD45RA, 
CCR7 and KLRG1 in each cluster group, n = 6. 
B) KLRG1 expression plot to show the levels of KLRG1 throughout all of the cluster 




5.4. T2D leads to the accumulation of KLRG1- EMRA T cells  
Following the t-SNE analysis, examination of KLRG1 levels via traditional flow 
cytometry analysis revealed that healthy age-matched control donors and T2D 
donors had both KLRG1+ and KLRG1– EMRA subsets (Figure 5.5A and B). However, 
T2D donors had a far greater number of the KLRG1- EMRA T cells than the control 
donors (Figure 5.5A and B).  
 
5.5. T2D EMRA T cells have a distinct senescent phenotype  
These changes to the composition of the EMRA population in T2D raised the question 
as to whether this subset was distinct from control EMRA T cells. To investigate this, 
Cellular Senescence RT2 Profiler Arrays were used to assess the expression levels of 
84 different senescence markers in T2D and healthy age-matched control CD8+ EMRA 
T cells. T2D and control EMRA T cells shared numerous similarities, however there 
were a large proportion of genes which were altered in T2D EMRA T cells compared 
with control EMRAs, with 45% of genes being up-regulated and 20% down-regulated 













Figure 5.5: KLRG1 levels in CD8+ T cell subset  
A) Representative dot plots of KLRG1 + and – subsets in CD8+ EMRA T cells 
B) Quantification of KLRG1 + and – subsets in CD8+ EMRA T cells in T2D and healthy 
age-matched control donors. Data expressed as mean ± SEM, n = 13 control, 13 
T2D. P values were determined using a two-way ANOVA with Bonferroni multiple 







Figure 5.6: Changes in gene expression in T2D EMRAs compared with control EMRAs.  
A) Scatterplot and B) pie chart illustrating the number of genes measured in the RT2 
Cellular Senescence Array that were upregulated, unchanged and downregulated in 
the T2D EMRAs compared to the control EMRAs. Fold change cut-off < 2, Control n = 





5.5.1. T2D EMRA exhibit evidence of DNA damage but not telomere erosion 
Further investigating into the key genes involved in DNA damage and repair showed 
that p16 and p21 expression was increased in T2D EMRA cells, whereas p53 
expression was unchanged (Figure 5.7). Surprisingly, ATM expression was 
downregulated but CHEK1 and CHEK2, which are downstream of the ATM and ATR 
(Awasthi et al., 2015), were increased (Figure 5.7). The most striking observation 
amongst these genes was the dramatic upregulation of TERT – the catalytic subunit 
of telomerase (Figure 5.7).  
 
5.5.2. KLRG1- EMRAs have longer telomeres than KLRG1+ EMRAs  
To validate whether the increased TERT expression had any functional relevance we 
collaborated with Dr. Natalie Riddell at the University of Surrey to asses telomere 
length in CD8+ EMRA T cells. This was done by combining flow cytometry with 
fluorescence in situ hybridization (flow-FISH). The incorporation of a nucleic acid 
telomeric probe (CCCTAA)3 conjugated to Cy5 (TelCy5) during the flow-FISH protocol 
allowed for the quantification of telomeric DNA. No difference in TelCy5 was 
observed between control and T2D total EMRA T cells (Figure 5.8A). However, 
stratification using KLRG1 demonstrated that KLRG1- EMRAs have longer telomeres 












Figure 5.7: Expression of DNA damage and repair genes from the RT2 array 
Fold up- or Down-regulation of genes associated with DNA damage and repair in T2D 
CD8+ EMRA T cells compared to control CD8+ EMRAs. Fold change cut-off < 2, Control 








Figure 5.8: Telomere length in CD8+ EMRA T cells  
A) Telomere length measured using Cy5 labelled telomere probe in Flow-FISH in 
Control CD8+ EMRA T cells and T2D EMRA T cells. Data expressed as mean ± SEM, 
control n = 12, T2D n = 12. 
B) Telomere length measured using Cy5 labelled telomere probe in Flow-FISH with 
the KLRG1+ and – fractions of the T2D CD8+ EMRA T cell subset. Data expressed 








5.5.3. T2D EMRA T cells retain more proliferative capacity than control EMRAs 
Another striking difference was the upregulation of numerous genes involved in cell 
cycle progression in T2D CD8+ EMRA T cells compared with the healthy CD8+ EMRA T 
cells (Figure 5.9A). This suggested that these cells might retain more proliferative 
capacity than age-matched control EMRA T cells. To validate this, Ki-67 was used to 
assess proliferative activity in CD8+ EMRA T cells directly ex vivo. Intracellular staining 
did indeed reveal a significant increase in Ki-67 levels in the T2D CD8+ EMRA T cells 
compared to age-matched CD8+ EMRA T cells, which suggested that these cells have 
been arrested at an earlier stage prior to permanent cell cycle arrest (Figure 5.9B).  
 
5.6. T2D EMRA T cells are less cytotoxic than control EMRAs 
The role of a CD8+ T cells is to efficiently kill viral infected or cancerous cells. 
Consequently, cytotoxicity is a vital characteristic of CD8+ T cells and despite their 
senescent state CD8+ EMRA T cells still exhibit potent cytotoxic activity (Henson et 
al., 2014). To investigate cytotoxicity in T2D CD8+ EMRA T cells, we examined the 
levels of CD107a - a marker for T cell degranulation and cytotoxicity (Aktas et al., 
2009). Surprisingly, CD107a levels were lower in the T2D CD8+ EMRA T cells (Figure 
5.10A). Furthermore, KLRG1- EMRA T cells were shown to have even lower CD107a 
levels, demonstrating that these cells have reduced cytotoxic ability (Figure 5.10B). 
Collectively, these data suggest that T2D CD8+ EMRAs, in particular the KLRG1- 









Figure 5.9: Cyclin gene expression and Ki-67 levels in CD8+ EMRA T cells  
A) Fold up- or Down-regulation of genes associated with cell cycle progression from 
the RT2 array in T2D CD8+ EMRA T cells compared to control CD8+ EMRAs. Fold 
change cut-off < 2, Control n = 3, T2D n = 3. 
B) Ki-67 levels in control CD8+ EMRA T cells and T2D EMRA T cells. Data expressed 
as mean ± SEM, control n = 7, T2D n = 7. P value was determined using a paired 









Figure 5.10: CD107a levels in CD8+ EMRA T cells  
A) CD107a levels following 4-hour stimulation with aCD3 in the presence of 
monensin in control CD8+ EMRA T cells and T2D EMRA T cells. Data expressed as 
mean ± SEM, control n = 6, T2D n = 6. 
B) CD107a levels following 4-hour stimulation with aCD3 in the presence of 
monensin in T2D CD8+ EMRA KLRG1+ and KLRG1- T cells. Data expressed as mean 





5.7. Premature senescence in T2D is driven by inflammation 
The data so far in this chapter has highlighted the existence of a KLRG1- EMRA 
population in the T2D compartment. This population is likely being driven to 
senescence prematurely rather than reaching conventional replicative senescence as 
a result of repeated stimulation. This raised the question as to what was driving the 
premature senescence. To assess this, a series of culture experiments were 
conducted using the sera from T2D and healthy age-matched control donors to 
determine if certain factors within the sera could trigger less differentiated T cells to 
senesce.  
 
5.7.1. Optimisation of sera culture experiment 
In order to assess whether or not sera from T2D patients would result in an increase 
in senescent T cells, the culture conditions for the experiment first needed to be 
optimised. To do this, PBMCs from a young healthy donor were isolated and then 
cultured in either low (2.5mM) or high glucose (25mM) conditions with or without 
10% FCS for 7 days before flow cytometry analysis. Cells cultured in both low and 
high glucose conditions remained viable at day 7 (Figure 5.11A). Furthermore, no 
difference in the percentage of CD8+ EMRA T cells was observed between the low or 
high glucose conditions (Figure 5.11B). To mimic the environment of T2D, PBMCs 
from a young donor were then cultured for 7 days in high glucose media with either 









Figure 5.11: Optimisation of sera experiments 
A) Percentage of live PBMCs following 7 days in culture with 10% FCS and either low 
(2.5mM) and high (25mM) glucose determined using ZOMBIE_NIR. Data 
expressed as mean ± SEM, Low n = 4, High n = 4. 
B) Percentage of CD8+ EMRA T cells following 7 days in culture with 10% FCS and 
either low (2.5mM) and high (25mM) glucose. Data expressed as mean ± SEM, 





5.7.2. T2D sera drives T cell senescence 
PBMCs were phenotyped at day 0, 3 and 7 to assess whether these conditions could 
drive senescence. At day 3, no difference was observed between the two different 
conditions; however, by day 7 both the control sera and T2D sera resulted in an 
increase in the CD8+ EMRA T cell population (Figure 5.12A and B). Despite both 
conditions driving an increase in EMRA T cells, the T2D sera drove this process 
significantly more than the control sera (Figure 5.12B). Moreover, t-SNE cluster 
analysis revealed that the type of EMRA T cells being generated in the two sera 
conditions were distinct (Figure 5.13 and 5.14). Incubation with control sera gave rise 
to an increase in EMRA 2, whereas T2D sera gave rise to both EMRA 1 and i-EMRAs 
(Figure 5.13 and 5.14).  
 
5.7.3. T2D sera is highly pro-inflammatory 
Following these culture experiments, the cytokine profiles of the sera was 
investigated. Both control and T2D sera contained numerous pro-inflammatory 
cytokines (Figure 5.15A and B). However, the T2D sera contained far more cytokines 
and the amounts of these cytokines were much greater than in the control sera 
(Figure 5.15B). Furthermore, a number of cytokines, such as CXCL1, IL-6, IL-8 and IL-
16 were all present in the T2D sera, but completely absent in all control sera (Figure 
5.15B). As a result of these sera experiments, we termed KLRG1- EMRA T cells 









Figure 5.12: T2D sera drives CD8+ EMRA T cell generation   
A) Representative dot plots of CD45RA/CD27 gating in CD8+ T cells at day 0 and 7 of 
culture with 10% sera from age-matched control and T2D donors.  
B) Quantification of CD8+ EMRA T cells following incubating with 10% sera from age-
matched control and T2D donors. Data expressed as mean ± SEM, n = 3 per 











Figure 5.13: t-SNE cluster analysis of CD8+ T cells after incubation with T2D or control 
sera 
A) Clusterplot analysis of CD8+ T cells following a 7-day incubation with either 
healthy age-matched control sera or T2D sera using CD27, CD28, CD45RA, CCR7 
and KLRG1, n = 3. 
B) Rate change plot showing the change in the percentage of cells in each group 






Figure 5.14: Marker expression data from t-SNE analysis  
A) Heatmap to show protein levels of cell surface markers CD27, CD28, CD45RA, 
CCR7 and KLRG1 in each cluster group, n = 3. 
B) KLRG1 expression plot to show the levels of KLRG1 throughout all of the cluster 







Figure 5.15: T2D sera is pro-inflammatory    
A) Representative cytokine array membrane following incubation with control or 
T2D serum.  
B) Cytokine levels quantified from the pixel densities of cytokine spots on the array 




5.8. T2D alters the mitochondrial and metabolic properties of CD8+ EMRAs 
As illustrated in chapter 4, mitochondrial health and cellular metabolism can heavily 
influence the onset of senescence in T cells. CD8+ EMRA T cells exhibit mitochondrial 
dysfunction and impaired OXPHOS (Henson et al., 2014); however, the metabolic 
properties of CD8+ EMRA T cells from people living with T2D are not known.  
 
5.8.1. Mitochondrial ROS is elevated in T2D EMRA T cells 
Mitochondrial mass, determined by Mitotracker green staining, was unchanged 
between the healthy age-matched control and T2D CD8+ EMRA T cells (Figure 5.16A 
and B). However, data obtained from the RT2 array suggested that mitochondria from 
T2D EMRAs may be producing more ROS than the control EMRAs. NADPH oxidases 4 
(NOX4) was greatly upregulated in the T2D CD8+ EMRA T cells compared with the 
control EMRAs (Figure 5.17A). NOX enzymes, including NOX4, are major contributors 
to cellular ROS (Chen et al., 2012). The mitochondrial gene; superoxide dismutase 2 
(SOD2), which converts superoxide by-products of OXPHOS into hydrogen peroxide 
and diatomic oxygen (Velarde et al., 2012), was also elevated (Figure 5.17A). This is 
likely an attempt to reduce the damaging effects of elevated oxidative stress. 
However, despite SOD2 expression, examination of mtROS levels using the 
mitochondrial superoxide indicator MitoSOX revealed that mtROS levels were higher 











Figure 5.16: Mitochondrial mass in CD8+ EMRA T cells    
A) Representative histograms of Mitotracker Green in control and T2D CD8+ EMRAs. 
B) Quantification of mitochondrial mass using MitoTracker Green in control and T2D 
CD8+ EMRA T cells. Data expressed as mean ± SEM, control n = 7, T2D n = 7. 



















Figure 5.17: Elevated oxidative stress in T2D CD8+ EMRA T cells 
A) Fold up- or Down-regulation of genes associated with oxidative stress from the 
RT2 array in T2D CD8+ EMRA T cells compared to control CD8+ EMRAs. Fold change 
cut-off < 2, Control n = 3, T2D n = 3. 
B) MitoSOX staining in control CD8+ EMRA T cells and T2D EMRA T cells. Data 





5.8.2. CD8+ T cells from T2D donors have increased oxidative respiration 
Due to the limiting cell numbers obtained from T2D blood donations, it was not 
possible to acquire enough CD8+ EMRA T cells to run a seahorse assay on this subset. 
Instead, the bioenergetic profiles of whole CD8+ T cells from healthy age-matched 
control and T2D donors were compared (Figure 5.18A). Interestingly, CD8+ T cells 
from people living with T2D had an elevated basal and maximal OCR (Figure 5.18B 
and C).  
 
5.8.3. T2D CD8+ EMRA T cells have altered nutrient uptake  
To determine what energy source could be fuelling the increased oxidative 
respiration, we assessed nutrient uptake using the fluorescent glucose analogue; 2-
NBDG. and fluorescent palmitate analogue; BODIPY C 16. Unsurprisingly, we found 
that T2D CD8+ EMRA T cells displayed a lack of glucose uptake (Figure 5.19A). In 
contrast, CD8+ EMRA T cells from T2D donors had a significant increase in palmitate 
uptake (Figure 5.19B). Consequently, we used the Seahorse XF Palmitate assay to 
investigate FAO. In this assay, cells were first conditioned in nutrient-limited media, 
then treated with palmitate and subjected to the sequential injection of respiration 
modulators (Figure 5.20A). FAO was found to be significantly decreased in T2D CD8+ 
T cells (Figure 5.20B and C). As palmitate was not being utilised, we subsequently 
used Nile Red to assess the accumulation of lipid droplets. This revealed that CD8+ 
EMRA T cells from T2D donors were indeed accumulating lipid (Figure 5.21). 
Unfortunately, these experiments were unable to determine what energy source was 







Figure 5.18: The bioenergetics profiles of T2D CD8+ T cells 
(A) OCR of the CD8+ T cells was measured after 15-minute stimulation with 0.5 μg/ml 
anti-CD3 and 5 ng/ml IL-2, cells were subjected to a mitochondrial stress test using 
indicated mitochondrial inhibitors. Data are representative of 4 independent 
experiments. (B) Basal OCR and (C) the Maximal respiration after 15-minute 








Figure 5.19: Glucose and lipid uptake in CD8+ EMRA T cells 
A) Glucose uptake assessed using 2-NBDG in glucose free media. Representative dot 
plots and cumulative data. Data expressed as mean ± SEM, control n = 8, T2D n = 
8. P value was determined using an unpaired T-test, p* = 0.0330. 
B) Lipid uptake assessed using BODIPY C16. Representative dot plots and cumulative 
data. Data expressed as mean ± SEM, control n = 8, T2D n = 6. P value was 







Figure 5.20: Fatty acid oxidation in CD8+ T cells 
A) FAO determined OCR of the CD8+ T cells was measured after 15-minute 
stimulation with 0.5 μg/ml anti-CD3 and 5 ng/ml IL-2 and incubation with palmitate. 
Cells were subjected to a mitochondrial stress test using indicated mitochondrial 
inhibitors. Data are representative of 2 independent experiments.  
B) Basal OCR and C) the Maximal respiration after 15-minute stimulation with 0.5 









Figure 5.21: Lipid droplets in CD8+ EMRA T cells 
A) Representative histograms of Nile Red in control and T2D CD8+ EMRAs. 
B) Quantification of Lipid droplets using Nile Red in control and T2D CD8+ EMRA T 





5.8.4. T2D EMRA T cells have reduced AMPK levels 
Following the observations of altered nutrient usage in T2D CD8+ EMRA T cells we 
examined the levels of intracellular phosphorylated AMP-activated protein kinase 
(pAMPK) - a master regulator of both glucose and lipid metabolism (Hardie et al., 
2012). pAMPK was found to be reduced in the T2D CD8+ EMRA T cells compared to 
















Figure 5.22: pAMPK levels in CD8+ EMRA T cells 
A) Representative histograms of pAMPK in control and T2D CD8+ EMRAs. 
B) Quantification of pAMPK in control and T2D CD8+ EMRA T cells. Data expressed 






Many chronic viral infections, such as CMV and HIV, have been shown to drive 
replicative senescence in the CD8+ T cell lineage (Ibegbu et al., 2006; Voehringer et 
al., 2001). For example, in people living with HIV, a large portion of virus specific CD8+ 
T cells are shown to express high levels of KLRG1. In this chapter we show the 
accumulation of CD8+ EMRA T cells in people living with T2D. Interestingly, a 
subgroup of these EMRA T cells had no KLRG1. Moreover, T2D CD8+ EMRA T cells 
were found to retain some of their proliferative capacity and had longer telomeres, 
demonstrating that they were not generated through telomere dysfunction and 
replicative senescence. Surprisingly, CHEK1 and CHEK2 were upregulated despite a 
downregulation of the ATM. Furthermore, while p53 remained unchanged, p21 and 
to a lesser extent p16 were both up-regulated in T2D EMRA T cells. Interestingly, 
CHEK2 has been previously shown to activate p21 in a p53-independent manner in 
the absence of telomere dysfunction (Aliouat-Denis et al., 2005). Therefore, a similar 
telomere-independent mechanism involving the CHEK proteins and p21 may be 
responsible for the induction of premature senescence in people living with T2D.  
 
We believe that the complete absence of KLRG1 and the positioning of the i-EMRA 
population next to the true naïve T cells in the t-SNE analysis is a big indicator as to 
the origin of these cells. Rather than differentiating from EM T cells as conventional 
EMRAs do, we propose that naïve CD8+ T cells are forced into a prematurely 
senescent state due to the elevated inflammatory milieu these cells are subjected to 




Inflammation plays a key role in the pathogenesis of many age-related and chronic 
diseases. For instance, in atherosclerosis immune cells are a key pathological player 
during plaque development and rupture (Libby, 2012). Numerous studies have 
shown a correlation between elevated levels of inflammatory markers, such as IL-6 
and C-reactive protein, and the risk of cardiovascular events (Kaptoge et al., 2012; 
Pai et al., 2004; Ridker et al., 2000). Here we found that despite the use of medication 
to manage their disease, T2D donors exhibited greater levels of cytokines in their 
blood serum when compared to the age-matched control donors. Of course, it is hard 
to assess what the impact of these medications themselves are; however, it would 
be extremely difficult to find a large enough cohort of people living with T2D that did 
not manage their disease through medication to test this. Nevertheless, we found no 
correlation between the number of medications people were on and the number of 
CD8+ EMRA T cells. As a result, we are confident that the increase in CD8+ EMRA T 
cells, particularly the i-EMRA subset, is not due to the use of medication.  
 
TNF- plays a crucial role in insulin resistance and the onset of T2D (Moller, 2000). 
Moreover, in vitro studies have shown that incubation with TNF- is enough to drive 
the onset of T cell senescence. However, no TNF- was detected in the sera of T2D 
donors in our cytokine array analysis. We propose that this is due to both the short-
lived nature of TNF- and the fact that all of our study participants had been living 
with T2D for on average 15 years and were managing their disease through 
numerous medications. As a result, the chronic inflammatory cytokine signatures of 




present during the onset of disease. At this stage it is not possible to attribute the 
generation of i-EMRAs to a particular cytokine or combination of cytokines. In order 
to assess this, future experiments are be needed to fully appreciate the contribution 
of each cytokine to i-EMRA generation. 
 
In addition to the inflammatory environment T cells are exposed to in T2D, senescent 
T cells themselves are highly pro-inflammatory and secrete a SASP (Callender, Carroll, 
Beal, et al., 2018), reinforcing both the senescent and inflammatory phenotype of 
these cells. Due to the elevated inflammatory environment that generates i-EMRA T 
cells in people living with T2D, we hypothesise that CD8+ i-EMRA T cells will be more 
pro-inflammatory than conventional EMRAs. However, in order to confirm this 
hypothesis a robust assessment of secreted cytokines is needed. Moreover, the 
levels of secreted perforin and granzyme B should also be examined in order to 
validate that this subset has reduced cytotoxic ability. Clinically, these potential 
functional impairments may be responsible, at least in part, for some of the classical 
diabetic complications, such as increased rates of infection and impaired wound 
healing (Galkowska et al., 2005; Muller et al., 2005). Therefore, to confirm this we 
also propose conducting additional cytotoxic T cell killing assays.  
 
Since T2D is also characterised by metabolic imbalances we began to investigate T 
cell metabolism in the context of T2D. Mitochondria from T2D CD8+ T cells had higher 
oxidative capacity and T2D EMRA T cells had increased levels of mtROS compared to 




vascular complications such as atherosclerosis (Baynes and Thorpe, 1999; Dandona 
et al., 1996). Additionally, mtROS can also result in DNA damage and senescence 
(Davalli et al., 2016). Therefore, elevated mtROS levels in T2D CD8+ EMRA T cells could 
result in damage to the extracellular environment in which they sit and may also act 
to reinforce the senescent phenotype of these cells.  
 
In activated T cells, insulin stimulates glucose uptake and enhances T cells 
responsiveness and energy requirements necessary for appropriate T cell function 
(Stentz and Kitabchi, 2005). It is therefore unsurprising that CD8+ EMRA T cells in the 
context of T2D, characterised by insulin resistance and deficiency, had impaired 
glucose uptake. pAMPK, which is usually activated in response to low glucose and 
positively regulates FAO (Hardie, 2004; Xu et al., 2012), was reduced in T2D CD8+ 
EMRA T cells. Decreased AMPK could provide an explanation for the lack of FAO in 
these cells. Furthermore, if AMPK levels were increased in these cells FAO may be 
restored and the accumulation of FA in lipid droplets avoided.   
 
As glucose uptake and FAO are both impaired, it remains unclear what energy source 
T2D CD8+ T cells are metabolising. One potential candidate is glutamine. Glutamine-
mediated metabolism has been shown to be important during T cell activation and 
proliferation (Carr et al., 2010). Furthermore, it is used in many cell types in order to 
fuel oxidative metabolism under stress conditions (Chendong et al., 2009; Le et al., 




et al., 2015), the reduced pAMPK levels in T2D EMRAs mean this hypothesis is 
unclear. To be certain, specific glutamine uptake assays need to be conducted.  
 
Due to limiting cell numbers and fluorescent markers we had available we were 
unable to examine mitochondrial and metabolic differences between the 
conventional EMRA and i-EMRA subsets. However, moving forward it would be 
interesting to see whether or not the differences described here are present in both 
EMRA subsets or not. 
 
In summary, this chapter identified a previously undescribed subset of CD8+ KLRG1- 
EMRA T cells, which are derived through chronic inflammation; i-EMRAs. The fact 
that these cells are derived from an early subset and not through replicative 
senescence suggests there is potential to reverse this phenotype. Furthermore, 
impaired nutrient uptake and usage in CD8+ EMRA T cells in T2D is likely to have a 
profound effect on T cell function. Consequently, a better understanding of these 
metabolic abnormalities is crucial as metabolic manipulation of these cells may 






Chapter six: General Discussion 
The overall aim of this thesis was to examine the heterogeneous nature of senescent 
T cells. In particular, mechanisms of premature T cell senescence were investigated 
using T2D as a model system. Furthermore, the relationship between cell metabolism 
and the extent of T cell senescence was compared in the CD8+ and CD4+ T cell 
lineages.  
 
6.1. T cell senescence: more than proliferative stress 
It is well established that age significantly impacts the immune system, with age-
related defects leading to an inability to respond to new and emerging diseases, as 
well as decreased vaccination efficiency (Naylor et al., 2005). Many of these problems 
can be attributed to alterations in the T cell compartment, manifested by a reduced 
pool of naïve T cells and the accumulation of senescent T cells. To date, the majority 
of senescent T cell research has focused on replicative senescence in response to 
repeated antigen stimulation or chronic viral infections such as CMV (Chou and 
Effros, 2013). However, as premature senescence is well document in other cell types 
such as fibroblasts (Kang et al., 2011; Serrano et al., 1997; Toussaint et al., 2002), it 
is likely that T cells are also susceptible to the induction of premature senescence. 
 
At the molecular level p53, p16 and p21 have all been shown to play a role in 
replicative senescence; however, they can also act independently of telomere 




accumulate in human fibroblasts that have reached their finite proliferative capacity 
in culture (Alcorta et al., 1996; Hara et al., 1996; Wong and Riabowol, 1996), even in 
the absence of p53 (Jacobs and De Lange, 2004; Mirzayans et al., 2012). Furthermore, 
p16 is also associated with oncogene-mediated premature senescence (Serrano et 
al., 1997) and in other cell types, such as human mammary epithelial cells, it has been 
shown that senescence is not related to replicative senescence mediated by 
telomere erosion but instead by p16 upregulation (Ramirez et al., 2001, 2003). This 
type of p16 associated premature growth arrest, which occurs independently of 
telomere erosion, has been referred to as a stress senescence signalling pathway. 
However, as these premature phenotypes occur independent of proliferative 
lifespan and age some have argued that the term senescence should be avoided. 
Instead, some researchers refer to these stress induced phenotypes as stasis 
(Drayton and Peters, 2002; Feijoo et al., 2016). Controversially, p16 induced stasis 
has sometimes been seen as an experimental artefact due to inadequate culture 
conditions; however, others believe that stasis is an evolutionary defence mechanism 
that safeguards a cell from diverse stresses (Drayton and Peters, 2002). 
 
In T2D, we observed the accumulation of CD8+ EMRA T cells; however, in comparison 
to healthy age-matched control EMRA T cells, they expressed lower levels of p53 and 
retained more proliferative capacity. Consequently, we concluded that they 
resembled an earlier subset that had undergone premature senescence. Although 
these cells did have slightly elevated p16 levels, p16 is also expressed during effector 




T cell senescence (Goronzy and Weyand, 2019). On the other hand, p21 was highly 
elevated in T2D EMRA T cells. Therefore, we propose that the induction of premature 
senescence in these cells is through a p21 mediated mechanism independent of p53. 
Evidence for such mechanism has previously been shown in lung and breast 
carcinoma cells and immortalised human keratinocytes (Aliouat-Denis et al., 2005). 
The CHEK2 kinase, which was also elevated when we performed the cellular 
senescence array, was shown to be central in this pathway. To confirm this 
hypothesis, further validation that quantifies the protein levels of p21, p53 and p16 
in T2D EMRA T cells compared to healthy age-matched control EMRAs should be 
done. Furthermore, p21 knockdown and overexpression studies would be necessary 
to demonstrate the importance of p21. 
 
6.2. Inflammation and premature T cell ageing 
Here we used the model system of T2D to show that inflammation acts as a stress 
signal and drives the generation of premature i-EMRA T cells, which are 
phenotypically and functionally distinct from conventional EMRAs. It is likely that 
CD8+ i-EMRA T cells are also present in the general population; however, the elevated 
inflammation in T2D results in a greater accumulation of them. Conventional CD8+ 
EMRA T cells are highly associated with ageing. However, as i-EMRA T cell generation 
is determined by inflammation and not replicative senescence we propose that i-
EMRAs are not associated with ageing. To examine this, the frequency of CD8+ i-





The lack of KLRG1 on the surface of these cells make them easily detectable from 
conventional EMRAs. It also highlights that these cells are derived from a much 
earlier subset, most likely naïve T cells, rather than through the linear differentiation 
model that is usually associated with EMRA T cells. Interestingly, CD8+ resident 
memory (RM) EMRA T cells, which reside in the skin, have also been shown to express 
significantly lower KLRG1 than peripheral blood CD8+ EMRA T cells (Seidel et al., 
2018). Furthermore, similar to CD8+ i-EMRA T cells, CD8+ RM EMRA T cells have low 
cytotoxic potential. (Seidel et al., 2018).  
 
KLRG1 is not the only inhibitory receptor that accumulates on conventional CD8+ 
EMRA T cells. Other NK receptors, such as CD57 and NKG2A, also increase (Pereira et 
al., 2019; Tarazona et al., 2001). The expression of NK receptors in these cells has 
been proposed to contribute to the regulation of their cytotoxic abilities (Tarazona 
et al., 2001). Consequently, we believe that CD8+ i-EMRAs also lack other NK 
receptors, which contribute to their reduced cytotoxicity. However, further 
phenotypic examination of additional NK receptors should be conducted in order to 
confirm this.  
 
Inflammatory-derived T cell phenotypes are not restricted to T2D, as premature T 
cell ageing is observed in many inflammatory diseases. For example, in RA huge 
expansions of CD4+CD28- T cells occur (Martens et al., 1997). However, these cells 
express KLRG1, produce high levels of IFN- and display cytotoxic functions (Weyand 




cells. Following our work in T2D we have begun to study the generation of CD8+ i-
EMRA T cells in RA (Data not shown). Although this data is preliminary, it does suggest 
that CD8+ i-EMRA T cells are a common phenomenon of inflammatory diseases and 
not unique to T2D.  
 
Although we did not examine CD4+ T cell senescence in the context of T2D, in light of 
the differences we have observed between the CD8+ and CD4+ T cell lineage in 
healthy individuals, we believe it would be interesting to also assess these differences 
in T2D. However, it is important to note that the broader heterogeneity of the CD4+ 
T cell lineage mean this will require a much more extensive phenotyping panel. 
 
6.3. Reversal of CD8+ i-EMRA T cells 
In recent years, the experimental elimination of senescent cells has gained a lot of 
attention, as these studies have shown that the clearance of senescent cells increases 
healthy lifespan (Baker et al., 2011, 2016). However, these studies have all been 
conducted in mice and do not take into account the variety of effects that senescence 
has on different cell types. For instance, in T cells the increase in NK receptor 
expression that is associated with conventional CD8+ EMRAs suggests a possible re-
purposing of these cells. While T cell activities, such as rapid proliferation and TCR 
mediated activation may be restricted in CD8+ EMRAs (Cao et al., 2010), the 
accumulation of NK machinery allows these cells to maintain their cytotoxic abilities 
and conserves a level of immune protection in older individuals to compensate for 




conventional senescent T cells is likely to result in older individuals becoming more 
vulnerable. Conversely, CD8+ i-EMRA T cells have reduced cytotoxic ability and do not 
acquire NK machinery; therefore, it is currently unclear what role they play. 
Although, due to the elevated mtROS generation, we propose that these cells will do 
more harm than good, making them a pathogenic subset. Consequently, therapeutic 
intervention to reverse the premature senescent phenotype in these cells could be 
beneficial.  
 
It would be interesting to assess whether removal of inflammation alone would be 
enough for these cells to revert back into their previous state or whether the 
inflammation causes long term damage. Experimentally, this could be assessed 
through a series of long-term sera cultures; whereby, the senescent phenotype of T 
cells is examined before, during and after sera removal. Even if the removal of 
inflammation allowed these cells to revert back to their original state this would still 
be difficult to achieve clinically, as the outcomes of using anti-inflammatory drugs to 
treat diseases such as T2D have so far proven inconclusive (Pollack et al., 2016). For 
instance, although anti-TNF therapy has been shown to be beneficial in mouse 
models of insulin resistance and T2D (Hotamisligil et al., 1993), therapeutic benefits 
in human patients have been found to be limited (Bernstein et al., 2006; Dominguez 
et al., 2005; Stanley et al., 2011). Furthermore, anti-TNF medication in RA patients 
is associated with an increased risk to serious infections (Atzeni et al., 2012; Bongartz 
et al., 2006; Galloway et al., 2011). This demonstrates that we should avoid removing 




infections. Consequently, we believe a more targeted approach is needed to 
successfully manipulate CD8+ i-EMRA T cells. In order to achieve this a more detailed 
understanding of the underlying molecular mechanisms of CD8+ i-EMRA T cell 
generation will be needed.  
 
6.4. Cell metabolism and T cell senescence 
Metabolic regulation plays an important role during T cell senescence, with 
mitochondrial dysfunction and elevated aerobic glycolysis now identified as key 
features of CD8+ senescent T cells (Henson et al., 2014). Data presented in this thesis 
adds to this growing body of literature as it demonstrates a link between DNA 
damage, the induction of mitochondrial biogenesis and protection against the onset 
of senescence in the CD4+ compartment. Mechanistically, we were able to show that 
this was dependent on elevated levels of GATA3 (Figure 6.1). Although GATA3 was 
present in the CD8+ lineage, the levels were not sufficient to recruit PGC1 and 
induce mitochondria biogenesis. However, GATA3 overexpression studies should be 
conducted to determine if this mechanism could also occur in CD8+ T cells. 
Furthermore, assessment of GATA3 in T2D CD4+ T cells would be interesting to assess 





Figure 6.1: Schematic diagram illustrating the recruitment of the GATA3-PGC1 
complex in response to DNA damage in CD4+ T cells 
 
As discussion in chapter 4, we believe this phenomenon extends past the lymphocyte 
lineage and may play an important role in many cancers. GATA3-positive breast 
cancers are associated with chemotherapy resistance and we believe the 
accumulation of DNA damage generated during chemotherapy may recruit the 
GATA3-PGC1α complex. Additionally, despite the traditional view that cancer cells 
have dysfunctional mitochondria and rely on aerobic glycolysis; the Warburg effect 
(Schwartz et al., 2017; Warburg et al., 1927), recent data has illustrated that this 
might not always be the case. For example, the breast cancer cell line MCF-7 is more 




Furthermore, a previous study examining mitochondrial content and activity in 
human epithelial breast cancer cells demonstrated that these cells have high 
oxidative mitochondrial activity (Whitaker-Menezes et al., 2011). Although this study 
did not examine GATA3 expression, all of the breast cancer samples were selected 
based on the loss of stromal caveolin-1 (cav-1), a biomarker that is associated with 
increased oxidative stress and DNA damage (Witkiewicz et al., 2011). Consequently, 
it would be interesting to assess if the elevated oxidative capacity of these cells is the 
direct result of DNA damage induced recruitment of the GATA3-PGC1 complex.  
 
In T cells, the recruitment of the GATA3-PGC1 complex is protective against the 
onset of senescence; however, the consequences of improved mitochondria health 
and fitness in other cell types and under different conditions may have negative 
impacts. For instance, additional breast cancer and pancreatic studies have examined 
the positive correlation between PGC1 expression and increased metastasis (Lebleu 
et al., 2014; Viale et al., 2014). In these studies, PGC1 induced mitochondrial 
biogenesis and OXPHOS, which lead to increased cell invasion and migration (Lebleu 
et al., 2014). Therefore, elevating mitochondrial fitness and metabolic plasticity may 
not always be beneficial.  
 
To conclusively establish whether the DNA damage induced recruitment of the 
GATA3-PGC1 complex extends outside of the lymphocyte lineage we propose 
examining the relationship between mitochondria and GATA3 in other GATA3-





This thesis has demonstrated the highly heterogeneous nature of senescent T cells. 
This heterogeneity is a direct result of the different mechanisms that drive T cells into 
senescence. For example, repeated antigen stimulation in response to a chronic viral 
infection will result in a replicative senescence phenotype; whereas, extracellular 
stresses such as inflammation will result in a premature senescence phenotype 
(Figure 6.2). Furthermore, each T cell lineage has its own distinct senescence 
phenotype with cell metabolism proving to be a crucial factor in determining the 
onset of senescence. Consequently, mitochondrial health and cellular metabolism 
should be included to better define the T cell senescence phenotype. These findings 
are important as a deeper understanding of the different drivers of senescence could 






Figure 6.2: Schematic diagram illustrating the different mechanisms responsible for 
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